NOR-SOLIDARITY First Interim Report

Inge Christoffer Olsen, PhD

04 January, 2021


Table of Contents

# Introduction


This is the report for the first interim analysis of the NOR-SOLIDARITY trial. The data are based on an export from the Viedoc electronic data capture at “2020-11-21 15:46:31” system time stamped “ous\_20201121\_154631”. While the results are based on real data, the treatment allocation has been drawn randomly for this report. Thus, this is a mock-up report intended to show how the final report will look like, without showing the actual results of the trial and the treatment differences. There were 181 included patients.

# Inclusion status




## Inclusion rate



## Inclusion by hospital



## By treatment



# Patient flow

## Note: Using an external vector in selections is ambiguous.  
## ℹ Use `all\_of(group)` instead of `group` to silence this message.  
## ℹ See <https://tidyselect.r-lib.org/reference/faq-external-vector.html>.  
## This message is displayed once per session.

Patient flow total

|  |  |
| --- | --- |
| Parameter | Total |
| Enrolled | 186 (100%) |
| Randomised | 185 (99.5%) |
| Included in FAS | 181 (97.3%) |
| Excluded from FAS, No post-randomisation information | 4 (2.2%) |
| Excluded from FAS, incorrect inclusion | 1 (0.5%) |

Patient flow by arm

|  |  |  |  |
| --- | --- | --- | --- |
| Parameter | SOC | SOC + HCQ | SOC + Remdesivir |
| Randomised | 88 (100%) | 54 (100%) | 43 (100%) |
| Included in FAS | 87 (98.9%) | 52 (96.3%) | 42 (97.7%) |
| Excluded from FAS, No post-randomisation information | 1 (1.1%) | 1 (1.9%) | 1 (2.3%) |
| Excluded from FAS, incorrect inclusion | 0 (0%) | 1 (1.9%) | 0 (0%) |

Patient flow during study (FAS)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Reason | Standard of care (SOC) | Remdesivir + SOC | Hydroxychloroquine + SOC | Total |
| Voluntary discontinuation by the patient | 3 | 4 | 0 | 7 |
| Patient lost to follow-up | 2 | 2 | 2 | 6 |
| Death | 2 | 5 | 5 | 12 |
| Other | 4 | 2 | 0 | 6 |
| Completed | 76 | 29 | 45 | 150 |

# Demographics

Demographics, all patients (FAS)

|  |  |
| --- | --- |
| Parameter | All patients (N=181) |
| **Demographics** |  |
| Age (years) | 59.8 (15.3) |
| Female, n (%) | 62 (34.3%) |
| Body Mass Index (kg/m2) | 28 (5) |
| Body Mass Index (kg/m2) | 27 (25 - 31) |
| Symptoms prior to admission (days) | 8 (4.9) |
| P/F-ratio at admittance (kPa) | 41 (13) |
| P/F-ratio < 40kPa, n (%) | 77 (43%) |
| Temperature (°C) | 37.4 (0.9) |
| Admitted to ward, n(%) | 171 (94.5%) |
| Admitted to ICU, n(%) | 10 (5.5%) |
| WHO Moderate disease state (4-5), n(%) | 171 (94.5%) |
| WHO Severe disease state (6-9), n(%) | 10 (5.5%) |
| WHO Severe disease state (6), n(%) | 5 (2.8%) |
| WHO Severe disease state (5), n(%) | 90 (49.7%) |
| **Comorbidities** |  |
| Chronic cardiac disease, including congenital heart disease | 28 (15.6%) |
| Chronic pulmonary disease, n(%) | 10 (5.6%) |
| Ever smoking, n(%) | 71 (39.4%) |
| Hypertension, n(%) | 55 (30.6%) |
| Diabetes, n(%) | 31 (17.2%) |
| Obese (BMI > 30 kg/m2), n(%) | 44 (26.8%) |
| **Co-medications** |  |
| Steroids | 8 (4.5%) |
| Other immunomodulatory drugs | 8 (4.5%) |
| ACE inhibitor | 12 (6.7%) |
| AT-II blockers | 30 (16.8%) |
| **Hematology** |  |
| Hemoglobin (g/dL) | 13.2 (12.3 - 14.1) |
| WBC (x109/L) | 6.2 (4.7 - 8.7) |
| Neutrophils (x109/L) | 4.3 (3 - 6.6) |
| Lymphocytes (x109/L) | 1.1 (0.8 - 1.4) |
| Platelet counts (x10^9/L) | 202.5 (158.5 - 270.5) |
| **Inflammatory markers** |  |
| CRP (mg/L) | 70 (36.5 - 137.5) |
| Procalcitonin (µg/L) | 0.12 (0.1 - 0.21) |
| Ferritin (µg/L) | 613 (319 - 1173) |
| **Other** |  |
| LDH (U/L) | 277 (214 - 360) |
| D-dimer (mg/L FEU) | 0.68 (0.45 - 1.12) |
| AST | 39 (27.2 - 59) |
| ALT | 33 (20 - 58) |
| eGFR (mL/min/1.73 m2) | 89.7 (74.2 - 105.5) |
| **Viral count** |  |
| Viral count (log10 counts/1000 cells) | 2 (1.6) |
| **Anti-SARS-CoV-2 Antibodies** |  |
| **Supplementary baseline information** |  |
| Systolic Blood Pressure (mmHg) | 125 (18) |
| Diastolic Blood Pressure (mmHg) | 74 (11) |
| Mean Arterial Blood Pressure (mmHg) | 91 (12) |
| SOFA score | 1.6 (1.6) |
| Chronic kidney disease, n(%) | 11 (6.1%) |
| Autoimmune disease, n(%) | 8 (4.4%) |
| Cognitive impairment/dementia, n(%) | 4 (2.2%) |
| Neurological disorder, n(%) | 7 (3.9%) |
| Cancer, n(%) | 13 (7.2%) |
| Cirrhosis, n(%) | 0 (0%) |
| Asthma, n(%) | 22 (12.2%) |
| HIV, n(%) | 0 (0%) |
| Active TB, n(%) | 0 (0%) |
| Note, all percentages are given with observed values in the denominator, missing values discarded |  |

Demographics, all arms (FAS)

|  |  |  |  |
| --- | --- | --- | --- |
| Parameter | SOC (N=87) | SOC + HCQ (N=52) | SOC + Remdesivir (N=42) |
| **Demographics** |  |  |  |
| Age (years) | 58.2 (14.6) | 59.1 (16.7) | 63.8 (14.7) |
| Female, n (%) | 29 (33.3%) | 15 (28.8%) | 18 (42.9%) |
| Body Mass Index (kg/m2) | 29 (5) | 27 (4) | 27 (5) |
| Body Mass Index (kg/m2) | 28 (25 - 33) | 27 (24 - 29) | 27 (25 - 29) |
| Symptoms prior to admission (days) | 8 (4.9) | 7.3 (4.7) | 9 (5.2) |
| P/F-ratio at admittance (kPa) | 42 (12) | 43 (13) | 38 (15) |
| P/F-ratio < 40kPa, n (%) | 37 (43%) | 20 (39.2%) | 20 (47.6%) |
| Temperature (°C) | 37.3 (1) | 37.5 (0.9) | 37.5 (0.9) |
| Admitted to ward, n(%) | 84 (96.6%) | 49 (94.2%) | 38 (90.5%) |
| Admitted to ICU, n(%) | 3 (3.4%) | 3 (5.8%) | 4 (9.5%) |
| WHO Moderate disease state (4-5), n(%) | 83 (95.4%) | 49 (94.2%) | 39 (92.9%) |
| WHO Severe disease state (6-9), n(%) | 4 (4.6%) | 3 (5.8%) | 3 (7.1%) |
| WHO Severe disease state (6), n(%) | 2 (2.3%) | 2 (3.8%) | 1 (2.4%) |
| WHO Severe disease state (5), n(%) | 41 (47.1%) | 24 (46.2%) | 25 (59.5%) |
| **Comorbidities** |  |  |  |
| Chronic cardiac disease, including congenital heart disease | 13 (15.1%) | 9 (17.3%) | 6 (14.3%) |
| Chronic pulmonary disease, n(%) | 3 (3.5%) | 4 (7.7%) | 3 (7.1%) |
| Ever smoking, n(%) | 34 (39.5%) | 22 (42.3%) | 15 (35.7%) |
| Hypertension, n(%) | 24 (27.9%) | 18 (34.6%) | 13 (31%) |
| Diabetes, n(%) | 13 (15.1%) | 7 (13.5%) | 11 (26.2%) |
| Obese (BMI > 30 kg/m2), n(%) | 26 (32.5%) | 10 (22.7%) | 8 (20%) |
| **Co-medications** |  |  |  |
| Steroids | 3 (3.5%) | 3 (5.9%) | 2 (4.8%) |
| Other immunomodulatory drugs | 3 (3.5%) | 3 (5.9%) | 2 (4.8%) |
| ACE inhibitor | 6 (7%) | 3 (5.9%) | 3 (7.1%) |
| AT-II blockers | 13 (15.1%) | 7 (13.7%) | 10 (23.8%) |
| **Hematology** |  |  |  |
| Hemoglobin (g/dL) | 13.1 (12.1 - 14.1) | 13.6 (13 - 14.4) | 12.9 (11.6 - 14) |
| WBC (x109/L) | 6.3 (4.5 - 9) | 6.2 (4.8 - 8.1) | 6 (4.8 - 7.9) |
| Neutrophils (x109/L) | 4.5 (2.8 - 7) | 4.6 (3 - 6.4) | 3.9 (3.2 - 5.6) |
| Lymphocytes (x109/L) | 1.1 (0.8 - 1.3) | 1.1 (0.8 - 1.4) | 1.1 (0.7 - 1.5) |
| Platelet counts (x10^9/L) | 204 (151.2 - 268.2) | 197 (163 - 268.8) | 208.5 (170.2 - 271.2) |
| **Inflammatory markers** |  |  |  |
| CRP (mg/L) | 70.5 (40.8 - 138.8) | 75 (43 - 137.8) | 61 (27 - 127) |
| Procalcitonin (µg/L) | 0.12 (0.1 - 0.2) | 0.12 (0.1 - 0.2) | 0.15 (0.1 - 0.39) |
| Ferritin (µg/L) | 626 (321.5 - 1116) | 578 (315.2 - 1209.5) | 573 (316 - 1194) |
| **Other** |  |  |  |
| LDH (U/L) | 279 (216 - 368) | 290 (216 - 353.5) | 274 (209 - 325) |
| D-dimer (mg/L FEU) | 0.6 (0.41 - 1.18) | 0.64 (0.5 - 1.02) | 0.9 (0.51 - 1.12) |
| AST | 41 (29 - 57) | 43 (27 - 65) | 32.5 (24 - 61.2) |
| ALT | 39 (22 - 61) | 30 (22.5 - 58.5) | 23.5 (18.2 - 49) |
| eGFR (mL/min/1.73 m2) | 91.6 (79.8 - 106) | 88.8 (76.1 - 104.6) | 83.3 (67.8 - 97.3) |
| **Viral count** |  |  |  |
| Viral count (log10 counts/1000 cells) | 1.9 (1.6) | 2.1 (1.7) | 2.2 (1.5) |
| **Anti-SARS-CoV-2 Antibodies** |  |  |  |
| **Supplementary baseline information** |  |  |  |
| Systolic Blood Pressure (mmHg) | 125 (18) | 125 (17) | 125 (18) |
| Diastolic Blood Pressure (mmHg) | 73 (11) | 74 (12) | 73 (12) |
| Mean Arterial Blood Pressure (mmHg) | 91 (12) | 91 (12) | 91 (12) |
| SOFA score | 1.8 (1.8) | 1.3 (1.4) | 1.5 (1.5) |
| Chronic kidney disease, n(%) | 5 (5.8%) | 2 (3.8%) | 4 (9.5%) |
| Autoimmune disease, n(%) | 3 (3.5%) | 3 (5.8%) | 2 (4.8%) |
| Cognitive impairment/dementia, n(%) | 2 (2.3%) | 1 (1.9%) | 1 (2.4%) |
| Neurological disorder, n(%) | 3 (3.5%) | 3 (5.8%) | 1 (2.4%) |
| Cancer, n(%) | 6 (7%) | 6 (11.5%) | 1 (2.4%) |
| Cirrhosis, n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Asthma, n(%) | 6 (7%) | 11 (21.2%) | 5 (11.9%) |
| HIV, n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Active TB, n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Note, all percentages are given with observed values in the denominator, missing values discarded |  |  |  |

Demographics, HCQ (FAS)

|  |  |  |
| --- | --- | --- |
| Parameter | SOC (N=54) | SOC + HCQ (N=52) |
| **Demographics** |  |  |
| Age (years) | 57.4 (16.4) | 59.1 (16.7) |
| Female, n (%) | 17 (31.5%) | 15 (28.8%) |
| Body Mass Index (kg/m2) | 28 (5) | 27 (4) |
| Body Mass Index (kg/m2) | 28 (25 - 31) | 27 (24 - 29) |
| Symptoms prior to admission (days) | 8.1 (5.5) | 7.3 (4.7) |
| P/F-ratio at admittance (kPa) | 40 (11) | 43 (13) |
| P/F-ratio < 40kPa, n (%) | 25 (46.3%) | 20 (39.2%) |
| Temperature (°C) | 37.2 (1) | 37.5 (0.9) |
| Admitted to ward, n(%) | 52 (96.3%) | 49 (94.2%) |
| Admitted to ICU, n(%) | 2 (3.7%) | 3 (5.8%) |
| WHO Moderate disease state (4-5), n(%) | 52 (96.3%) | 49 (94.2%) |
| WHO Severe disease state (6-9), n(%) | 2 (3.7%) | 3 (5.8%) |
| WHO Severe disease state (6), n(%) | 1 (1.9%) | 2 (3.8%) |
| WHO Severe disease state (5), n(%) | 30 (55.6%) | 24 (46.2%) |
| **Comorbidities** |  |  |
| Chronic cardiac disease, including congenital heart disease | 8 (15.1%) | 9 (17.3%) |
| Chronic pulmonary disease, n(%) | 1 (1.9%) | 4 (7.7%) |
| Ever smoking, n(%) | 22 (41.5%) | 22 (42.3%) |
| Hypertension, n(%) | 14 (26.4%) | 18 (34.6%) |
| Diabetes, n(%) | 9 (17%) | 7 (13.5%) |
| Obese (BMI > 30 kg/m2), n(%) | 14 (29.2%) | 10 (22.7%) |
| **Co-medications** |  |  |
| Steroids | 2 (3.8%) | 3 (5.9%) |
| Other immunomodulatory drugs | 2 (3.8%) | 3 (5.9%) |
| ACE inhibitor | 2 (3.8%) | 3 (5.9%) |
| AT-II blockers | 9 (17%) | 7 (13.7%) |
| **Hematology** |  |  |
| Hemoglobin (g/dL) | 13 (12.1 - 14.1) | 13.6 (13 - 14.4) |
| WBC (x109/L) | 6.6 (4.9 - 9.2) | 6.2 (4.8 - 8.1) |
| Neutrophils (x109/L) | 4.8 (3 - 7.4) | 4.6 (3 - 6.4) |
| Lymphocytes (x109/L) | 1.1 (0.8 - 1.5) | 1.1 (0.8 - 1.4) |
| Platelet counts (x10^9/L) | 217 (160 - 288.8) | 197 (163 - 268.8) |
| **Inflammatory markers** |  |  |
| CRP (mg/L) | 70.5 (40.8 - 137) | 75 (43 - 137.8) |
| Procalcitonin (µg/L) | 0.15 (0.1 - 0.25) | 0.12 (0.1 - 0.2) |
| Ferritin (µg/L) | 677 (312.2 - 1049.5) | 578 (315.2 - 1209.5) |
| **Other** |  |  |
| LDH (U/L) | 280 (220.8 - 358.8) | 290 (216 - 353.5) |
| D-dimer (mg/L FEU) | 0.6 (0.43 - 1.15) | 0.64 (0.5 - 1.02) |
| AST | 39.5 (28.8 - 58.2) | 43 (27 - 65) |
| ALT | 40.5 (22.2 - 63.8) | 30 (22.5 - 58.5) |
| eGFR (mL/min/1.73 m2) | 95.7 (83.2 - 106.1) | 88.8 (76.1 - 104.6) |
| **Viral count** |  |  |
| Viral count (log10 counts/1000 cells) | 1.8 (1.6) | 2.1 (1.7) |
| **Anti-SARS-CoV-2 Antibodies** |  |  |
| **Supplementary baseline information** |  |  |
| Systolic Blood Pressure (mmHg) | 128 (19) | 125 (17) |
| Diastolic Blood Pressure (mmHg) | 75 (10) | 74 (12) |
| Mean Arterial Blood Pressure (mmHg) | 93 (11) | 91 (12) |
| SOFA score | 1.7 (1.8) | 1.3 (1.4) |
| Chronic kidney disease, n(%) | 2 (3.8%) | 2 (3.8%) |
| Autoimmune disease, n(%) | 2 (3.8%) | 3 (5.8%) |
| Cognitive impairment/dementia, n(%) | 1 (1.9%) | 1 (1.9%) |
| Neurological disorder, n(%) | 0 (0%) | 3 (5.8%) |
| Cancer, n(%) | 3 (5.7%) | 6 (11.5%) |
| Cirrhosis, n(%) | 0 (0%) | 0 (0%) |
| Asthma, n(%) | 5 (9.4%) | 11 (21.2%) |
| HIV, n(%) | 0 (0%) | 0 (0%) |
| Active TB, n(%) | 0 (0%) | 0 (0%) |
| Note, all percentages are given with observed values in the denominator, missing values discarded |  |  |

Demographics, Remdesivir (FAS)

|  |  |  |
| --- | --- | --- |
| Parameter | SOC (N=57) | SOC + Remdesivir (N=42) |
| **Demographics** |  |  |
| Age (years) | 56.9 (12.1) | 63.8 (14.7) |
| Female, n (%) | 19 (33.3%) | 18 (42.9%) |
| Body Mass Index (kg/m2) | 29 (5) | 27 (5) |
| Body Mass Index (kg/m2) | 29 (26 - 33) | 27 (25 - 29) |
| Symptoms prior to admission (days) | 8.4 (5.8) | 9 (5.2) |
| P/F-ratio at admittance (kPa) | 43 (12) | 38 (15) |
| P/F-ratio < 40kPa, n (%) | 20 (35.7%) | 20 (47.6%) |
| Temperature (°C) | 37.4 (1) | 37.5 (0.9) |
| Admitted to ward, n(%) | 55 (96.5%) | 38 (90.5%) |
| Admitted to ICU, n(%) | 2 (3.5%) | 4 (9.5%) |
| WHO Moderate disease state (4-5), n(%) | 54 (94.7%) | 39 (92.9%) |
| WHO Severe disease state (6-9), n(%) | 3 (5.3%) | 3 (7.1%) |
| WHO Severe disease state (6), n(%) | 2 (3.5%) | 1 (2.4%) |
| WHO Severe disease state (5), n(%) | 23 (40.4%) | 25 (59.5%) |
| **Comorbidities** |  |  |
| Chronic cardiac disease, including congenital heart disease | 8 (14.3%) | 6 (14.3%) |
| Chronic pulmonary disease, n(%) | 3 (5.4%) | 3 (7.1%) |
| Ever smoking, n(%) | 18 (32.1%) | 15 (35.7%) |
| Hypertension, n(%) | 17 (30.4%) | 13 (31%) |
| Diabetes, n(%) | 7 (12.5%) | 11 (26.2%) |
| Obese (BMI > 30 kg/m2), n(%) | 19 (35.8%) | 8 (20%) |
| **Co-medications** |  |  |
| Steroids | 2 (3.6%) | 2 (4.8%) |
| Other immunomodulatory drugs | 2 (3.6%) | 2 (4.8%) |
| ACE inhibitor | 5 (8.9%) | 3 (7.1%) |
| AT-II blockers | 9 (16.1%) | 10 (23.8%) |
| **Hematology** |  |  |
| Hemoglobin (g/dL) | 13.3 (12.1 - 14.1) | 12.9 (11.6 - 14) |
| WBC (x109/L) | 6.6 (4.3 - 8.7) | 6 (4.8 - 7.9) |
| Neutrophils (x109/L) | 3.8 (2.5 - 6.7) | 3.9 (3.2 - 5.6) |
| Lymphocytes (x109/L) | 1.1 (0.8 - 1.3) | 1.1 (0.7 - 1.5) |
| Platelet counts (x10^9/L) | 202 (144 - 263.2) | 208.5 (170.2 - 271.2) |
| **Inflammatory markers** |  |  |
| CRP (mg/L) | 67 (37.5 - 139.2) | 61 (27 - 127) |
| Procalcitonin (µg/L) | 0.1 (0.1 - 0.19) | 0.15 (0.1 - 0.39) |
| Ferritin (µg/L) | 622 (372.8 - 1153) | 573 (316 - 1194) |
| **Other** |  |  |
| LDH (U/L) | 279 (209 - 369) | 274 (209 - 325) |
| D-dimer (mg/L FEU) | 0.6 (0.41 - 1.2) | 0.9 (0.51 - 1.12) |
| AST | 45 (29 - 57.2) | 32.5 (24 - 61.2) |
| ALT | 41 (25.5 - 70) | 23.5 (18.2 - 49) |
| eGFR (mL/min/1.73 m2) | 91.8 (83.1 - 106.6) | 83.3 (67.8 - 97.3) |
| **Viral count** |  |  |
| Viral count (log10 counts/1000 cells) | 2 (1.7) | 2.2 (1.5) |
| **Anti-SARS-CoV-2 Antibodies** |  |  |
| **Supplementary baseline information** |  |  |
| Systolic Blood Pressure (mmHg) | 124 (18) | 125 (18) |
| Diastolic Blood Pressure (mmHg) | 73 (11) | 73 (12) |
| Mean Arterial Blood Pressure (mmHg) | 90 (12) | 91 (12) |
| SOFA score | 1.7 (1.5) | 1.5 (1.5) |
| Chronic kidney disease, n(%) | 3 (5.4%) | 4 (9.5%) |
| Autoimmune disease, n(%) | 2 (3.6%) | 2 (4.8%) |
| Cognitive impairment/dementia, n(%) | 1 (1.8%) | 1 (2.4%) |
| Neurological disorder, n(%) | 3 (5.4%) | 1 (2.4%) |
| Cancer, n(%) | 3 (5.4%) | 1 (2.4%) |
| Cirrhosis, n(%) | 0 (0%) | 0 (0%) |
| Asthma, n(%) | 4 (7.1%) | 5 (11.9%) |
| HIV, n(%) | 0 (0%) | 0 (0%) |
| Active TB, n(%) | 0 (0%) | 0 (0%) |
| Note, all percentages are given with observed values in the denominator, missing values discarded |  |  |

Missing values, all arms (FAS)

|  |  |  |  |
| --- | --- | --- | --- |
| Parameter | SOC (N=87) | SOC + HCQ (N=52) | SOC + Remdesivir (N=42) |
| **Demographics** |  |  |  |
| Age (years) | 0 (0%) | 0 (0%) | 0 (0%) |
| Female, n (%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Body Mass Index (kg/m2) | 7 (8%), 7 (8%) | 8 (15.4%), 8 (15.4%) | 2 (4.8%), 2 (4.8%) |
| Symptoms prior to admission (days) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| P/F-ratio at admittance (kPa) | 1 (1.1%) | 1 (1.9%) | 0 (0%) |
| P/F-ratio < 40kPa, n (%) | 1 (1.1%) | 1 (1.9%) | 0 (0%) |
| Temperature (°C) | 0 (0%) | 0 (0%) | 0 (0%) |
| Admitted to ward, n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Admitted to ICU, n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| WHO Moderate disease state (4-5), n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| WHO Severe disease state (6-9), n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| WHO Severe disease state (6), n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| WHO Severe disease state (5), n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| **Comorbidities** |  |  |  |
| Chronic cardiac disease, including congenital heart disease | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Chronic pulmonary disease, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Ever smoking, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Hypertension, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Diabetes, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Obese (BMI > 30 kg/m2), n(%) | 7 (8%) | 8 (15.4%) | 2 (4.8%) |
| **Co-medications** |  |  |  |
| Steroids | 1 (1.1%) | 1 (1.9%) | 0 (0%) |
| Other immunomodulatory drugs | 1 (1.1%) | 1 (1.9%) | 0 (0%) |
| ACE inhibitor | 1 (1.1%) | 1 (1.9%) | 0 (0%) |
| AT-II blockers | 1 (1.1%) | 1 (1.9%) | 0 (0%) |
| **Hematology** |  |  |  |
| Hemoglobin (g/dL) | 1 (1.1%) | 2 (3.8%) | 0 (0%) |
| WBC (x109/L) | 0 (0%) | 1 (1.9%) | 0 (0%) |
| Neutrophils (x109/L) | 3 (3.4%) | 6 (11.5%) | 1 (2.4%) |
| Lymphocytes (x109/L) | 2 (2.3%) | 6 (11.5%) | 1 (2.4%) |
| Platelet counts (x10^9/L) | 1 (1.1%) | 2 (3.8%) | 0 (0%) |
| **Inflammatory markers** |  |  |  |
| CRP (mg/L) | 1 (1.1%) | 0 (0%) | 1 (2.4%) |
| Procalcitonin (µg/L) | 32 (36.8%) | 14 (26.9%) | 12 (28.6%) |
| Ferritin (µg/L) | 4 (4.6%) | 2 (3.8%) | 3 (7.1%) |
| **Other** |  |  |  |
| LDH (U/L) | 2 (2.3%) | 5 (9.6%) | 1 (2.4%) |
| D-dimer (mg/L FEU) | 8 (9.2%) | 8 (15.4%) | 3 (7.1%) |
| AST | 6 (6.9%) | 3 (5.8%) | 2 (4.8%) |
| ALT | 2 (2.3%) | 2 (3.8%) | 4 (9.5%) |
| eGFR (mL/min/1.73 m2) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| **Viral count** |  |  |  |
| Viral count (log10 counts/1000 cells) | 28 (32.2%) | 11 (21.2%) | 9 (21.4%) |
| **Anti-SARS-CoV-2 Antibodies** |  |  |  |
| Sero converted (RBD ≤ 5) | 26 (29.9%) | 15 (28.8%) | 13 (31%) |
| **Supplementary baseline information** |  |  |  |
| Systolic Blood Pressure (mmHg) | 0 (0%) | 0 (0%) | 0 (0%) |
| Diastolic Blood Pressure (mmHg) | 0 (0%) | 0 (0%) | 0 (0%) |
| Mean Arterial Blood Pressure (mmHg) | 0 (0%) | 0 (0%) | 0 (0%) |
| SOFA score | 7 (8%) | 3 (5.8%) | 1 (2.4%) |
| Chronic kidney disease, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Autoimmune disease, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Cognitive impairment/dementia, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Neurological disorder, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Cancer, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Cirrhosis, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Asthma, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| HIV, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Active TB, n(%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
| Note, all percentages are given with observed values in the denominator, missing values discarded |  |  |  |

# Exposure

Exposure to study treatment

|  |  |  |
| --- | --- | --- |
| Parameter | SOC + HCQ (N=52) | SOC + Remdesivir (N=42) |
| Total dose (mg), median (IQR) | 1100 (850 - 3300) | 1100 (500 - 6400) |
| Treatment duration, median (IQR) | 6 (4 - 9) | 6 (3 - 9) |
| Number of doses given, median (IQR) | 7 (4 - 10) | 6 (4 - 10) |
| Patients with any treatment discrepencies, n (%) | 8 (33.3%) | 7 (29.2%) |

# Efficacy

## Mortality

### Descriptives

All arms (FAS)

|  |  |  |  |
| --- | --- | --- | --- |
| Treatment | # deaths | # randomised | % |
| Standard of care (SOC) | 2 | 87 | 2.3 |
| Hydroxychloroquine + SOC | 5 | 52 | 9.6 |
| Remdesivir + SOC | 5 | 42 | 11.9 |










HCQ (FAS)

|  |  |  |  |
| --- | --- | --- | --- |
| Treatment | # deaths | # randomised | % |
| Standard of care (SOC) | 1 | 54 | 1.9 |
| Hydroxychloroquine + SOC | 5 | 52 | 9.6 |

Remdesivir (FAS)

|  |  |  |  |
| --- | --- | --- | --- |
| Treatment | # deaths | # randomised | % |
| Standard of care (SOC) | 1 | 57 | 1.8 |
| Remdesivir + SOC | 5 | 42 | 11.9 |

### Plots







### Efficacy estimates

Relative risk estimates and p-values

|  |  |  |
| --- | --- | --- |
| Timeframe, Population | Relative risk | P-value |
| Full timeframe, All | Not applicable | 0.082 |
| Full timeframe, Hydroxychloroquine only | 4 (95% CI 0.81 to 19.82) | 0.090 |
| Full timeframe, Remdesivir only | 5.53 (95% CI 1.09 to 28.11) | 0.039 |
| Censored at 60 days, All | Not applicable | 0.100 |
| Censored at 60 days, Hydroxychloroquine only | 3.46 (95% CI 0.6 to 19.99) | 0.165 |
| Censored at 60 days, Remdesivir only | 5.53 (95% CI 1.09 to 28.11) | 0.039 |
| Censored at 28 days, All | Not applicable | 0.306 |
| Censored at 28 days, Hydroxychloroquine only | 3.46 (95% CI 0.6 to 19.99) | 0.165 |
| Censored at 28 days, Remdesivir only | 3.73 (95% CI 0.51 to 27.14) | 0.194 |

## Viral load

### Plots



### Marginal probability estimates by treatment group and difference

Estimated treatment effect, Hydroxychloroquine













|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Treatment | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | Slope 1st week | -0.191 | -0.269 | -0.113 | 0.000 |
| Hydroxychloroquine + SOC | Slope 1st week | -0.235 | -0.313 | -0.157 | 0.000 |
| Hydroxychloroquine + SOC | Difference in slope | -0.044 | -0.154 | 0.067 | 0.438 |
| Standard of care (SOC) | Level at day 10 | 0.443 | 0.072 | 0.815 | 0.019 |
| Hydroxychloroquine + SOC | Level at day 10 | 0.237 | -0.162 | 0.636 | 0.244 |
| Hydroxychloroquine + SOC | Difference at day 10 | -0.206 | -0.751 | 0.339 | 0.458 |

Estimated treatment effect, Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Treatment | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | Slope 1st week | -0.217 | -0.299 | -0.135 | 0.000 |
| Remdesivir + SOC | Slope 1st week | -0.164 | -0.248 | -0.079 | 0.000 |
| Remdesivir + SOC | Difference in slope | 0.053 | -0.065 | 0.171 | 0.376 |
| Standard of care (SOC) | Level at day 10 | 0.329 | -0.106 | 0.765 | 0.139 |
| Remdesivir + SOC | Level at day 10 | 0.737 | 0.343 | 1.130 | 0.000 |
| Remdesivir + SOC | Difference at day 10 | 0.407 | -0.180 | 0.994 | 0.174 |

## Viral load subgroup analyses

### Plots, Hydroxychloroquine



### Marginal probability estimates by treatment group and difference Hydroxychloroquine

Estimated treatment effect, Hydroxychloroquine

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | RBD < 5 | Slope 1st week by treatment and subgroup | -0.285 | -0.423 | -0.146 | 0.000 |
| Standard of care (SOC) | RBD ≥ 5 | Slope 1st week by treatment and subgroup | -0.139 | -0.246 | -0.032 | 0.011 |
| Hydroxychloroquine + SOC | RBD < 5 | Slope 1st week by treatment and subgroup | -0.293 | -0.406 | -0.179 | 0.000 |
| Hydroxychloroquine + SOC | RBD ≥ 5 | Slope 1st week by treatment and subgroup | -0.161 | -0.306 | -0.017 | 0.029 |
| Hydroxychloroquine + SOC | RBD < 5 | Treatment effect (Difference in slope) | -0.008 | -0.187 | 0.171 | 0.931 |
| Hydroxychloroquine + SOC | RBD ≥ 5 | Treatment effect (Difference in slope) | -0.022 | -0.202 | 0.158 | 0.809 |
| Hydroxychloroquine + SOC | RBD ≥ 5 | Treatment/Subgroup interaction | -0.014 | -0.268 | 0.239 | 0.912 |

Estimated treatment effect, Hydroxychloroquine

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | age < 60 years | Slope 1st week by treatment and subgroup | -0.253 | -0.374 | -0.132 | 0.000 |
| Standard of care (SOC) | age ≥ 60 years | Slope 1st week by treatment and subgroup | -0.149 | -0.255 | -0.043 | 0.006 |
| Hydroxychloroquine + SOC | age < 60 years | Slope 1st week by treatment and subgroup | -0.167 | -0.279 | -0.055 | 0.003 |
| Hydroxychloroquine + SOC | age ≥ 60 years | Slope 1st week by treatment and subgroup | -0.295 | -0.411 | -0.179 | 0.000 |
| Hydroxychloroquine + SOC | age < 60 years | Treatment effect (Difference in slope) | 0.086 | -0.079 | 0.251 | 0.308 |
| Hydroxychloroquine + SOC | age ≥ 60 years | Treatment effect (Difference in slope) | -0.146 | -0.303 | 0.011 | 0.068 |
| Hydroxychloroquine + SOC | age ≥ 60 years | Treatment/Subgroup interaction | -0.232 | -0.459 | -0.004 | 0.046 |

Estimated treatment effect, Hydroxychloroquine

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | High CRP | Slope 1st week by treatment and subgroup | -0.190 | -0.292 | -0.088 | 0.000 |
| Standard of care (SOC) | Low CRP | Slope 1st week by treatment and subgroup | -0.217 | -0.348 | -0.085 | 0.001 |
| Hydroxychloroquine + SOC | High CRP | Slope 1st week by treatment and subgroup | -0.232 | -0.340 | -0.123 | 0.000 |
| Hydroxychloroquine + SOC | Low CRP | Slope 1st week by treatment and subgroup | -0.237 | -0.359 | -0.115 | 0.000 |
| Hydroxychloroquine + SOC | High CRP | Treatment effect (Difference in slope) | -0.042 | -0.190 | 0.107 | 0.584 |
| Hydroxychloroquine + SOC | Low CRP | Treatment effect (Difference in slope) | -0.020 | -0.200 | 0.159 | 0.823 |
| Hydroxychloroquine + SOC | Low CRP | Treatment/Subgroup interaction | 0.021 | -0.212 | 0.254 | 0.859 |

Estimated treatment effect, Hydroxychloroquine

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | High Ferritin | Slope 1st week by treatment and subgroup | -0.179 | -0.281 | -0.077 | 0.001 |
| Standard of care (SOC) | Low Ferritin | Slope 1st week by treatment and subgroup | -0.235 | -0.370 | -0.101 | 0.001 |
| Hydroxychloroquine + SOC | High Ferritin | Slope 1st week by treatment and subgroup | -0.188 | -0.293 | -0.083 | 0.000 |
| Hydroxychloroquine + SOC | Low Ferritin | Slope 1st week by treatment and subgroup | -0.279 | -0.417 | -0.141 | 0.000 |
| Hydroxychloroquine + SOC | High Ferritin | Treatment effect (Difference in slope) | -0.009 | -0.155 | 0.138 | 0.909 |
| Hydroxychloroquine + SOC | Low Ferritin | Treatment effect (Difference in slope) | -0.044 | -0.237 | 0.149 | 0.658 |
| Hydroxychloroquine + SOC | Low Ferritin | Treatment/Subgroup interaction | -0.035 | -0.277 | 0.207 | 0.777 |













Estimated treatment effect, Hydroxychloroquine

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | Symptom duration < 7 days | Slope 1st week by treatment and subgroup | -0.263 | -0.392 | -0.135 | 0.000 |
| Standard of care (SOC) | Symptom duration ≥ 7 days | Slope 1st week by treatment and subgroup | -0.164 | -0.269 | -0.059 | 0.002 |
| Hydroxychloroquine + SOC | Symptom duration < 7 days | Slope 1st week by treatment and subgroup | -0.283 | -0.403 | -0.162 | 0.000 |
| Hydroxychloroquine + SOC | Symptom duration ≥ 7 days | Slope 1st week by treatment and subgroup | -0.202 | -0.312 | -0.092 | 0.000 |
| Hydroxychloroquine + SOC | Symptom duration < 7 days | Treatment effect (Difference in slope) | -0.019 | -0.195 | 0.157 | 0.830 |
| Hydroxychloroquine + SOC | Symptom duration ≥ 7 days | Treatment effect (Difference in slope) | -0.038 | -0.190 | 0.115 | 0.628 |
| Hydroxychloroquine + SOC | Symptom duration ≥ 7 days | Treatment/Subgroup interaction | -0.018 | -0.251 | 0.214 | 0.877 |

Estimated treatment effect, Hydroxychloroquine

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | High viral load | Slope 1st week by treatment and subgroup | -0.370 | -0.474 | -0.266 | 0.000 |
| Standard of care (SOC) | Low viral load | Slope 1st week by treatment and subgroup | -0.030 | -0.135 | 0.075 | 0.575 |
| Hydroxychloroquine + SOC | High viral load | Slope 1st week by treatment and subgroup | -0.384 | -0.483 | -0.286 | 0.000 |
| Hydroxychloroquine + SOC | Low viral load | Slope 1st week by treatment and subgroup | -0.063 | -0.171 | 0.044 | 0.248 |
| Hydroxychloroquine + SOC | High viral load | Treatment effect (Difference in slope) | -0.014 | -0.157 | 0.129 | 0.848 |
| Hydroxychloroquine + SOC | Low viral load | Treatment effect (Difference in slope) | -0.033 | -0.183 | 0.117 | 0.664 |
| Hydroxychloroquine + SOC | Low viral load | Treatment/Subgroup interaction | -0.019 | -0.227 | 0.188 | 0.855 |

### Plots Remdesivir



### Marginal probability estimates by treatment group and difference Remdesivir

Estimated treatment effect, Remdesivir

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | RBD < 5 | Slope 1st week by treatment and subgroup | -0.338 | -0.490 | -0.185 | 0.000 |
| Standard of care (SOC) | RBD ≥ 5 | Slope 1st week by treatment and subgroup | -0.105 | -0.237 | 0.028 | 0.123 |
| Remdesivir + SOC | RBD < 5 | Slope 1st week by treatment and subgroup | -0.225 | -0.353 | -0.096 | 0.001 |
| Remdesivir + SOC | RBD ≥ 5 | Slope 1st week by treatment and subgroup | -0.047 | -0.200 | 0.105 | 0.543 |
| Remdesivir + SOC | RBD < 5 | Treatment effect (Difference in slope) | 0.113 | -0.087 | 0.313 | 0.267 |
| Remdesivir + SOC | RBD ≥ 5 | Treatment effect (Difference in slope) | 0.057 | -0.145 | 0.259 | 0.579 |
| Remdesivir + SOC | RBD ≥ 5 | Treatment/Subgroup interaction | -0.056 | -0.340 | 0.228 | 0.700 |

Estimated treatment effect, Remdesivir

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | age < 60 years | Slope 1st week by treatment and subgroup | -0.216 | -0.316 | -0.116 | 0.000 |
| Standard of care (SOC) | age ≥ 60 years | Slope 1st week by treatment and subgroup | -0.258 | -0.401 | -0.115 | 0.000 |
| Remdesivir + SOC | age < 60 years | Slope 1st week by treatment and subgroup | -0.253 | -0.373 | -0.132 | 0.000 |
| Remdesivir + SOC | age ≥ 60 years | Slope 1st week by treatment and subgroup | -0.108 | -0.223 | 0.007 | 0.066 |
| Remdesivir + SOC | age < 60 years | Treatment effect (Difference in slope) | -0.037 | -0.194 | 0.120 | 0.645 |
| Remdesivir + SOC | age ≥ 60 years | Treatment effect (Difference in slope) | 0.150 | -0.033 | 0.334 | 0.108 |
| Remdesivir + SOC | age ≥ 60 years | Treatment/Subgroup interaction | 0.187 | -0.054 | 0.429 | 0.128 |

Estimated treatment effect, Remdesivir

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | High CRP | Slope 1st week by treatment and subgroup | -0.234 | -0.347 | -0.122 | 0.000 |
| Standard of care (SOC) | Low CRP | Slope 1st week by treatment and subgroup | -0.227 | -0.351 | -0.104 | 0.000 |
| Remdesivir + SOC | High CRP | Slope 1st week by treatment and subgroup | -0.149 | -0.256 | -0.042 | 0.007 |
| Remdesivir + SOC | Low CRP | Slope 1st week by treatment and subgroup | -0.172 | -0.310 | -0.034 | 0.015 |
| Remdesivir + SOC | High CRP | Treatment effect (Difference in slope) | 0.085 | -0.070 | 0.241 | 0.283 |
| Remdesivir + SOC | Low CRP | Treatment effect (Difference in slope) | 0.056 | -0.130 | 0.241 | 0.557 |
| Remdesivir + SOC | Low CRP | Treatment/Subgroup interaction | -0.030 | -0.272 | 0.212 | 0.811 |

Estimated treatment effect, Remdesivir

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | High Ferritin | Slope 1st week by treatment and subgroup | -0.193 | -0.306 | -0.080 | 0.001 |
| Standard of care (SOC) | Low Ferritin | Slope 1st week by treatment and subgroup | -0.257 | -0.379 | -0.135 | 0.000 |
| Remdesivir + SOC | High Ferritin | Slope 1st week by treatment and subgroup | -0.147 | -0.266 | -0.027 | 0.017 |
| Remdesivir + SOC | Low Ferritin | Slope 1st week by treatment and subgroup | -0.188 | -0.319 | -0.056 | 0.005 |
| Remdesivir + SOC | High Ferritin | Treatment effect (Difference in slope) | 0.047 | -0.118 | 0.211 | 0.580 |
| Remdesivir + SOC | Low Ferritin | Treatment effect (Difference in slope) | 0.069 | -0.110 | 0.248 | 0.448 |
| Remdesivir + SOC | Low Ferritin | Treatment/Subgroup interaction | 0.023 | -0.221 | 0.266 | 0.854 |

Estimated treatment effect, Remdesivir





|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | Symptom duration < 7 days | Slope 1st week by treatment and subgroup | -0.286 | -0.396 | -0.175 | 0.000 |
| Standard of care (SOC) | Symptom duration ≥ 7 days | Slope 1st week by treatment and subgroup | -0.169 | -0.294 | -0.044 | 0.008 |
| Remdesivir + SOC | Symptom duration < 7 days | Slope 1st week by treatment and subgroup | -0.202 | -0.324 | -0.081 | 0.001 |
| Remdesivir + SOC | Symptom duration ≥ 7 days | Slope 1st week by treatment and subgroup | -0.154 | -0.268 | -0.040 | 0.008 |
| Remdesivir + SOC | Symptom duration < 7 days | Treatment effect (Difference in slope) | 0.083 | -0.081 | 0.247 | 0.322 |
| Remdesivir + SOC | Symptom duration ≥ 7 days | Treatment effect (Difference in slope) | 0.015 | -0.154 | 0.184 | 0.861 |
| Remdesivir + SOC | Symptom duration ≥ 7 days | Treatment/Subgroup interaction | -0.068 | -0.304 | 0.168 | 0.572 |

Estimated treatment effect, Remdesivir

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment | Subgroup | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | High viral load | Slope 1st week by treatment and subgroup | -0.386 | -0.490 | -0.282 | 0.000 |
| Standard of care (SOC) | Low viral load | Slope 1st week by treatment and subgroup | -0.043 | -0.159 | 0.073 | 0.467 |
| Remdesivir + SOC | High viral load | Slope 1st week by treatment and subgroup | -0.280 | -0.376 | -0.185 | 0.000 |
| Remdesivir + SOC | Low viral load | Slope 1st week by treatment and subgroup | 0.035 | -0.095 | 0.166 | 0.593 |
| Remdesivir + SOC | High viral load | Treatment effect (Difference in slope) | 0.106 | -0.035 | 0.247 | 0.142 |
| Remdesivir + SOC | Low viral load | Treatment effect (Difference in slope) | 0.079 | -0.096 | 0.253 | 0.377 |
| Remdesivir + SOC | Low viral load | Treatment/Subgroup interaction | -0.027 | -0.252 | 0.197 | 0.812 |

## Respiratory failure by pO2/FiO2-ratio

### Plots



### Marginal probability estimates by treatment group and difference

Estimated treatment effect, Hydroxychloroquine

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Treatment | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | Slope 1st week | 1.287 | 0.688 | 1.886 | 0.000 |
| Hydroxychloroquine + SOC | Slope 1st week | 0.141 | -0.447 | 0.728 | 0.638 |
| Hydroxychloroquine + SOC | Difference in slope | -1.146 | -1.985 | -0.307 | 0.007 |
| Standard of care (SOC) | Level at day 10 | 57.491 | 51.155 | 63.828 | 0.000 |
| Hydroxychloroquine + SOC | Level at day 10 | 51.690 | 45.453 | 57.927 | 0.000 |
| Hydroxychloroquine + SOC | Difference at day 10 | -5.801 | -14.692 | 3.090 | 0.201 |

Estimated treatment effect, Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Treatment | Explanation | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Standard of care (SOC) | Slope 1st week | 0.855 | 0.345 | 1.366 | 0.001 |
| Remdesivir + SOC | Slope 1st week | -0.113 | -0.655 | 0.429 | 0.682 |
| Remdesivir + SOC | Difference in slope | -0.969 | -1.713 | -0.224 | 0.011 |
| Standard of care (SOC) | Level at day 10 | 54.982 | 49.889 | 60.075 | 0.000 |
| Remdesivir + SOC | Level at day 10 | 42.081 | 36.613 | 47.549 | 0.000 |
| Remdesivir + SOC | Difference at day 10 | -12.901 | -20.373 | -5.428 | 0.001 |

## Dichotomous endpoints

### Descriptives

Hydroxycholoquine

|  |  |  |
| --- | --- | --- |
| Outcome | Standard of care (SOC) | Hydroxychloroquine + SOC |
| Mortality during hospitalisation | 1 (1.9%) | 5 (9.6%) |
| Mortality (censored at day 28) | 1 (1.9%) | 4 (7.7%) |
| Mortality (censored at day 60) | 1 (1.9%) | 4 (7.7%) |
| WHO disease state progression | 6 (11.1%) | 11 (21.2%) |
| WHO disease state progression (censoreda at day 28) | 6 (11.1%) | 11 (21.2%) |
| WHO disease state progression (censoreda at day 60) | 6 (11.1%) | 11 (21.2%) |
| Mechanical ventilation during hospitalisation | 3 (5.6%) | 4 (7.7%) |
| Mechanical ventilation (censored at day 28) | 3 (5.6%) | 4 (7.7%) |
| Mechanical ventilation (censored at day 60) | 3 (5.6%) | 4 (7.7%) |
| Admission to ICU during hospitalisation | 8 (14.8%) | 10 (19.2%) |
| Admission to ICU (censored at day 28) | 8 (14.8%) | 10 (19.2%) |
| Admission to ICU (censored at day 60) | 8 (14.8%) | 10 (19.2%) |

Figures are number of patients with the outcome and percent (%)

Remdesivir

|  |  |  |
| --- | --- | --- |
| Outcome | Standard of care (SOC) | Remdesivir + SOC |
| Mortality during hospitalisation | 1 (1.8%) | 5 (11.9%) |
| Mortality (censored at day 28) | 1 (1.8%) | 3 (7.1%) |
| Mortality (censored at day 60) | 1 (1.8%) | 5 (11.9%) |
| WHO disease state progression | 9 (15.8%) | 9 (21.4%) |
| WHO disease state progression (censoreda at day 28) | 9 (15.8%) | 9 (21.4%) |
| WHO disease state progression (censoreda at day 60) | 9 (15.8%) | 9 (21.4%) |
| Mechanical ventilation during hospitalisation | 5 (8.8%) | 8 (19%) |
| Mechanical ventilation (censored at day 28) | 5 (8.8%) | 8 (19%) |
| Mechanical ventilation (censored at day 60) | 5 (8.8%) | 8 (19%) |
| Admission to ICU during hospitalisation | 9 (15.8%) | 12 (28.6%) |
| Admission to ICU (censored at day 28) | 9 (15.8%) | 12 (28.6%) |
| Admission to ICU (censored at day 60) | 9 (15.8%) | 12 (28.6%) |

Figures are number of patients with the outcome and percent (%)

### Marginal probability estimates by treatment group and difference

Hydroxychloroquine

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | Standard of care (SOC) | Hydroxychloroquine + SOC | Estimated marginal treatment effect |
| Mortality during hospitalisation | 1.9% (-1.7 to 5.4) | 9.6% (1.6 to 17.6) | 7.8% (-1 to 16.5) |
| Mortality (censored at day 28) | 1.9% (-1.7 to 5.4) | 7.7% (0.4 to 14.9) | 5.8% (-2.2 to 13.9) |
| Mortality (censored at day 60) | 1.9% (-1.7 to 5.4) | 7.7% (0.4 to 14.9) | 5.8% (-2.2 to 13.9) |
| WHO disease state progression | 11.1% (2.7 to 19.5) | 21.2% (10.1 to 32.3) | 10% (-3.9 to 24) |
| WHO disease state progression (censoreda at day 28) | 11.1% (2.7 to 19.5) | 21.2% (10.1 to 32.3) | 10% (-3.9 to 24) |
| WHO disease state progression (censoreda at day 60) | 11.1% (2.7 to 19.5) | 21.2% (10.1 to 32.3) | 10% (-3.9 to 24) |
| Mechanical ventilation during hospitalisation | 5.6% (-0.6 to 11.7) | 7.7% (0.4 to 14.9) | 2.1% (-7.3 to 11.6) |
| Mechanical ventilation (censored at day 28) | 5.6% (-0.6 to 11.7) | 7.7% (0.4 to 14.9) | 2.1% (-7.3 to 11.6) |
| Mechanical ventilation (censored at day 60) | 5.6% (-0.6 to 11.7) | 7.7% (0.4 to 14.9) | 2.1% (-7.3 to 11.6) |
| Admission to ICU during hospitalisation | 14.8% (5.3 to 24.3) | 19.2% (8.5 to 29.9) | 4.4% (-9.9 to 18.7) |
| Admission to ICU (censored at day 28) | 14.8% (5.3 to 24.3) | 19.2% (8.5 to 29.9) | 4.4% (-9.9 to 18.7) |
| Admission to ICU (censored at day 60) | 14.8% (5.3 to 24.3) | 19.2% (8.5 to 29.9) | 4.4% (-9.9 to 18.7) |

Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | Standard of care (SOC) | Remdesivir + SOC | Estimated marginal treatment effect |
| Mortality during hospitalisation | 1.8% (-1.7 to 5.2) | 11.9% (2.1 to 21.7) | 10.2% (-0.2 to 20.5) |
| Mortality (censored at day 28) | 1.8% (-1.7 to 5.2) | 7.1% (-0.6 to 14.9) | 5.4% (-3.1 to 13.9) |
| Mortality (censored at day 60) | 1.8% (-1.7 to 5.2) | 11.9% (2.1 to 21.7) | 10.2% (-0.2 to 20.5) |
| WHO disease state progression | 15.8% (6.3 to 25.3) | 21.4% (9 to 33.8) | 5.6% (-10 to 21.2) |
| WHO disease state progression (censoreda at day 28) | 15.8% (6.3 to 25.3) | 21.4% (9 to 33.8) | 5.6% (-10 to 21.2) |
| WHO disease state progression (censoreda at day 60) | 15.8% (6.3 to 25.3) | 21.4% (9 to 33.8) | 5.6% (-10 to 21.2) |
| Mechanical ventilation during hospitalisation | 8.8% (1.4 to 16.1) | 19% (7.2 to 30.9) | 10.3% (-3.7 to 24.2) |
| Mechanical ventilation (censored at day 28) | 8.8% (1.4 to 16.1) | 19% (7.2 to 30.9) | 10.3% (-3.7 to 24.2) |
| Mechanical ventilation (censored at day 60) | 8.8% (1.4 to 16.1) | 19% (7.2 to 30.9) | 10.3% (-3.7 to 24.2) |
| Admission to ICU during hospitalisation | 15.8% (6.3 to 25.3) | 28.6% (14.9 to 42.2) | 12.8% (-3.8 to 29.4) |
| Admission to ICU (censored at day 28) | 15.8% (6.3 to 25.3) | 28.6% (14.9 to 42.2) | 12.8% (-3.8 to 29.4) |
| Admission to ICU (censored at day 60) | 15.8% (6.3 to 25.3) | 28.6% (14.9 to 42.2) | 12.8% (-3.8 to 29.4) |

## Inflammatory laboratory parameters

### Descriptives

CRP (mg/L), HCQ

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| 0 days | Mean (SD) | 93.08 (70.73) | 95.32 (70.98) |
| 0 days | Median [IQR] | 70.5 [40.75 - 137] | 75 [43 - 137.75] |
| 0 days | Missing / Non-Missing | 0 / 54 | 0 / 52 |
| 1 days | Mean (SD) | 96.93 (80.24) | 91.72 (64.17) |
| 1 days | Median [IQR] | 66 [46.5 - 127.5] | 80 [42.5 - 130.5] |
| 1 days | Missing / Non-Missing | 11 / 43 | 5 / 46 |
| 2 days | Mean (SD) | 92.12 (85.86) | 81.61 (56.14) |
| 2 days | Median [IQR] | 58 [36 - 120] | 67 [38.5 - 111.5] |
| 2 days | Missing / Non-Missing | 9 / 43 | 4 / 44 |
| 3 days | Mean (SD) | 78.43 (71.96) | 84.9 (55.33) |
| 3 days | Median [IQR] | 61.5 [20.5 - 106.25] | 71.5 [46.25 - 120.5] |
| 3 days | Missing / Non-Missing | 5 / 42 | 4 / 40 |
| 4 days | Mean (SD) | 77.73 (65.65) | 76.13 (51.54) |
| 4 days | Median [IQR] | 65.5 [27.5 - 100] | 63 [36.5 - 120.5] |
| 4 days | Missing / Non-Missing | 5 / 32 | 6 / 34 |
| 5 days | Mean (SD) | 64.93 (62.61) | 70.99 (52.92) |
| 5 days | Median [IQR] | 45 [25 - 83] | 63.5 [35 - 97.75] |
| 5 days | Missing / Non-Missing | 4 / 29 | 7 / 30 |
| 6 days | Mean (SD) | 50.88 (52.58) | 85.98 (67.51) |
| 6 days | Median [IQR] | 34 [15.5 - 65] | 63.5 [38.5 - 125.5] |
| 6 days | Missing / Non-Missing | 2 / 27 | 7 / 24 |
| 7 days | Mean (SD) | 41.8 (42.2) | 75.5 (60.74) |
| 7 days | Median [IQR] | 29 [10.35 - 61.5] | 49 [27 - 105] |
| 7 days | Missing / Non-Missing | 1 / 23 | 3 / 25 |
| 8 days | Mean (SD) | 41.8 (38.18) | 87.43 (85.88) |
| 8 days | Median [IQR] | 29 [13 - 58] | 55 [22 - 110] |
| 8 days | Missing / Non-Missing | 2 / 17 | 4 / 21 |
| 9 days | Mean (SD) | 34.52 (41.22) | 90.83 (84.55) |
| 9 days | Median [IQR] | 22 [6.55 - 42.75] | 53.5 [22.5 - 160.5] |
| 9 days | Missing / Non-Missing | 3 / 14 | 4 / 18 |
| 10 days | Mean (SD) | 34.59 (41.17) | 54.87 (74.35) |
| 10 days | Median [IQR] | 20 [9.85 - 32.75] | 22 [7.58 - 70.25] |
| 10 days | Missing / Non-Missing | 0 / 14 | 5 / 14 |
| 11 days | Mean (SD) | 28.75 (36.96) | 104.84 (146.35) |
| 11 days | Median [IQR] | 12 [8 - 40.5] | 44 [11 - 101] |
| 11 days | Missing / Non-Missing | 2 / 12 | 4 / 10 |
| 12 days | Mean (SD) | 54.7 (67.25) | 100.7 (211.6) |
| 12 days | Median [IQR] | 26.1 [7.25 - 80.75] | 11 [4.8 - 42] |
| 12 days | Missing / Non-Missing | 5 / 8 | 3 / 9 |
| 13 days | Mean (SD) | 58.75 (80.21) | 110 (142.27) |
| 13 days | Median [IQR] | 24 [10.25 - 63.25] | 70 [17 - 101] |
| 13 days | Missing / Non-Missing | 3 / 8 | 5 / 5 |
| 14 days | Mean (SD) | 14.8 (12.96) | 43.78 (65.14) |
| 14 days | Median [IQR] | 12 [5 - 22] | 18 [13 - 20] |
| 14 days | Missing / Non-Missing | 0 / 7 | 1 / 5 |

CRP (mg/L), Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| 0 days | Mean (SD) | 91.41 (73.39) | 84.32 (63.53) |
| 0 days | Median [IQR] | 67 [37.5 - 139.25] | 61 [27 - 127] |
| 0 days | Missing / Non-Missing | 1 / 56 | 1 / 41 |
| 1 days | Mean (SD) | 94.58 (77.05) | 92.39 (66.8) |
| 1 days | Median [IQR] | 77 [35.5 - 136.5] | 86 [54 - 118] |
| 1 days | Missing / Non-Missing | 9 / 48 | 9 / 33 |
| 2 days | Mean (SD) | 76.39 (74.35) | 101.49 (80.59) |
| 2 days | Median [IQR] | 52 [22.5 - 105.5] | 92.5 [45.25 - 130.25] |
| 2 days | Missing / Non-Missing | 6 / 51 | 5 / 36 |
| 3 days | Mean (SD) | 78.12 (78.33) | 97.97 (80.35) |
| 3 days | Median [IQR] | 53 [18 - 105] | 91 [30 - 132.25] |
| 3 days | Missing / Non-Missing | 9 / 41 | 8 / 28 |
| 4 days | Mean (SD) | 85.31 (89.1) | 111.42 (98.52) |
| 4 days | Median [IQR] | 55 [25 - 115.25] | 96 [46 - 141] |
| 4 days | Missing / Non-Missing | 7 / 34 | 3 / 29 |
| 5 days | Mean (SD) | 73.6 (75.85) | 122.85 (101.1) |
| 5 days | Median [IQR] | 48 [22 - 97] | 91 [32 - 178] |
| 5 days | Missing / Non-Missing | 5 / 30 | 4 / 25 |
| 6 days | Mean (SD) | 63.86 (65.17) | 102.43 (104.29) |
| 6 days | Median [IQR] | 39 [18.25 - 65.75] | 55 [18 - 156.5] |
| 6 days | Missing / Non-Missing | 2 / 28 | 3 / 27 |
| 7 days | Mean (SD) | 73.51 (71.88) | 110.57 (101.66) |
| 7 days | Median [IQR] | 53 [12 - 143] | 69 [20.5 - 220.5] |
| 7 days | Missing / Non-Missing | 2 / 21 | 2 / 23 |
| 8 days | Mean (SD) | 85.72 (89.25) | 91.52 (87.21) |
| 8 days | Median [IQR] | 58 [21 - 97] | 54.5 [25 - 173.75] |
| 8 days | Missing / Non-Missing | 3 / 17 | 3 / 20 |
| 9 days | Mean (SD) | 86.17 (94.48) | 71.99 (72.16) |
| 9 days | Median [IQR] | 59 [12 - 110] | 34 [13.5 - 123.5] |
| 9 days | Missing / Non-Missing | 5 / 11 | 1 / 19 |
| 10 days | Mean (SD) | 59.49 (87.85) | 67.65 (65.24) |
| 10 days | Median [IQR] | 26 [6 - 66] | 52.5 [9 - 103.5] |
| 10 days | Missing / Non-Missing | 2 / 13 | 2 / 14 |
| 11 days | Mean (SD) | 57.46 (83.17) | 68.22 (46.52) |
| 11 days | Median [IQR] | 18 [7 - 73.5] | 75.5 [32.75 - 102.5] |
| 11 days | Missing / Non-Missing | 2 / 11 | 3 / 12 |
| 12 days | Mean (SD) | 66.83 (97.06) | 76.73 (43.66) |
| 12 days | Median [IQR] | 13.6 [7.25 - 90.5] | 89 [42 - 108.5] |
| 12 days | Missing / Non-Missing | 3 / 8 | 2 / 11 |
| 13 days | Mean (SD) | 79.33 (95.14) | 91.66 (80.37) |
| 13 days | Median [IQR] | 14 [11 - 187] | 81 [29 - 115.5] |
| 13 days | Missing / Non-Missing | 1 / 9 | 1 / 12 |
| 14 days | Mean (SD) | 85.08 (120.48) | 65.04 (78.48) |
| 14 days | Median [IQR] | 27.5 [10.5 - 105.5] | 31.5 [9.28 - 78.25] |
| 14 days | Missing / Non-Missing | 1 / 8 | 0 / 10 |

Ferritin (µg/L), HCQ

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| 0 days | Mean (SD) | 1208.54 (3215.44) | 892.02 (801.85) |
| 0 days | Median [IQR] | 677 [312.25 - 1049.5] | 578 [315.25 - 1209.5] |
| 0 days | Missing / Non-Missing | 2 / 52 | 2 / 50 |
| 1 days | Mean (SD) | 1390.8 (3148.91) | 959.29 (887.23) |
| 1 days | Median [IQR] | 889 [386.25 - 1155.5] | 545 [353 - 1305.5] |
| 1 days | Missing / Non-Missing | 20 / 34 | 20 / 31 |
| 2 days | Mean (SD) | 1097.95 (1702.45) | 966.38 (771.84) |
| 2 days | Median [IQR] | 828 [417 - 1255.5] | 785 [384 - 1262] |
| 2 days | Missing / Non-Missing | 9 / 43 | 11 / 37 |
| 3 days | Mean (SD) | 843.09 (636.23) | 1359.09 (1036.35) |
| 3 days | Median [IQR] | 822 [325.5 - 1083.5] | 938 [682 - 1759] |
| 3 days | Missing / Non-Missing | 12 / 35 | 11 / 33 |
| 4 days | Mean (SD) | 994.11 (780.36) | 1628.83 (1657.46) |
| 4 days | Median [IQR] | 778 [415.5 - 1298] | 870 [581 - 2076] |
| 4 days | Missing / Non-Missing | 10 / 27 | 17 / 23 |
| 5 days | Mean (SD) | 847.87 (588.87) | 1348.95 (1235.85) |
| 5 days | Median [IQR] | 667 [443.5 - 1031.5] | 804 [616 - 1886] |
| 5 days | Missing / Non-Missing | 10 / 23 | 16 / 21 |
| 6 days | Mean (SD) | 768.13 (456.93) | 1446.55 (1314.96) |
| 6 days | Median [IQR] | 807 [386.5 - 917.5] | 1132 [656.25 - 1599.75] |
| 6 days | Missing / Non-Missing | 5 / 24 | 9 / 22 |
| 7 days | Mean (SD) | 850.29 (439.33) | 1325.25 (889.82) |
| 7 days | Median [IQR] | 859 [413 - 1258] | 1284.5 [613 - 2012.25] |
| 7 days | Missing / Non-Missing | 3 / 21 | 8 / 20 |
| 8 days | Mean (SD) | 595.23 (319.91) | 1151.12 (806.97) |
| 8 days | Median [IQR] | 525 [384 - 880] | 1020 [669 - 1782] |
| 8 days | Missing / Non-Missing | 6 / 13 | 8 / 17 |
| 9 days | Mean (SD) | 597.08 (286.79) | 1080.39 (791.73) |
| 9 days | Median [IQR] | 530 [411.25 - 731.25] | 906 [478 - 1661] |
| 9 days | Missing / Non-Missing | 5 / 12 | 9 / 13 |
| 10 days | Mean (SD) | 658 (292.19) | 1011.18 (585.79) |
| 10 days | Median [IQR] | 613 [395 - 939] | 1065 [726.5 - 1458.5] |
| 10 days | Missing / Non-Missing | 5 / 9 | 8 / 11 |
| 11 days | Mean (SD) | 505 (290.41) | 726.29 (590.38) |
| 11 days | Median [IQR] | 564 [212 - 771] | 728 [223 - 1126.5] |
| 11 days | Missing / Non-Missing | 5 / 9 | 7 / 7 |
| 12 days | Mean (SD) | 598.83 (224.24) | 519.2 (486.04) |
| 12 days | Median [IQR] | 691 [462.25 - 721] | 663 [41 - 664] |
| 12 days | Missing / Non-Missing | 7 / 6 | 7 / 5 |
| 13 days | Mean (SD) | 603 (253.97) | 992 (557.2) |
| 13 days | Median [IQR] | 712 [353.75 - 762.25] | 992 [795 - 1189] |
| 13 days | Missing / Non-Missing | 3 / 8 | 8 / 2 |
| 14 days | Mean (SD) | 539.2 (213.6) | 729.6 (534.93) |
| 14 days | Median [IQR] | 612 [376 - 698] | 553 [396 - 1126] |
| 14 days | Missing / Non-Missing | 2 / 5 | 1 / 5 |

Ferritin (µg/L), Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| 0 days | Mean (SD) | 1281.43 (3171.62) | 899.62 (873.33) |
| 0 days | Median [IQR] | 622 [372.75 - 1153] | 573 [316 - 1194] |
| 0 days | Missing / Non-Missing | 3 / 54 | 3 / 39 |
| 1 days | Mean (SD) | 1447.38 (3144.32) | 1042.96 (809.53) |
| 1 days | Median [IQR] | 739 [564.25 - 1260.5] | 900 [408.5 - 1477.5] |
| 1 days | Missing / Non-Missing | 23 / 34 | 15 / 27 |
| 2 days | Mean (SD) | 1078.96 (1693.25) | 1091.66 (878.68) |
| 2 days | Median [IQR] | 600 [411 - 1213] | 930.5 [471.5 - 1341.75] |
| 2 days | Missing / Non-Missing | 12 / 45 | 9 / 32 |
| 3 days | Mean (SD) | 921.08 (651.97) | 1129.22 (948.57) |
| 3 days | Median [IQR] | 790 [405.75 - 1162.75] | 952 [408 - 1379] |
| 3 days | Missing / Non-Missing | 14 / 36 | 13 / 23 |
| 4 days | Mean (SD) | 1229.57 (946.71) | 1293.09 (795.75) |
| 4 days | Median [IQR] | 966 [539.25 - 1585] | 1189 [845 - 1589] |
| 4 days | Missing / Non-Missing | 13 / 28 | 9 / 23 |
| 5 days | Mean (SD) | 1168.71 (884.96) | 1077.37 (626.18) |
| 5 days | Median [IQR] | 894.5 [500.75 - 1635.75] | 1000 [723.5 - 1273] |
| 5 days | Missing / Non-Missing | 11 / 24 | 10 / 19 |
| 6 days | Mean (SD) | 1022.08 (754.44) | 962.5 (514.41) |
| 6 days | Median [IQR] | 858 [387 - 1241] | 950.5 [678.75 - 1187.25] |
| 6 days | Missing / Non-Missing | 5 / 25 | 8 / 22 |
| 7 days | Mean (SD) | 1354.79 (1055.08) | 942.9 (540.99) |
| 7 days | Median [IQR] | 1138 [823 - 1653] | 888 [644.75 - 1364.25] |
| 7 days | Missing / Non-Missing | 4 / 19 | 5 / 20 |
| 8 days | Mean (SD) | 1202.64 (1162.93) | 924 (610.54) |
| 8 days | Median [IQR] | 903.5 [626.5 - 1411.75] | 750 [665.25 - 1112.25] |
| 8 days | Missing / Non-Missing | 6 / 14 | 9 / 14 |
| 9 days | Mean (SD) | 908.1 (638.11) | 863.94 (518.77) |
| 9 days | Median [IQR] | 753 [506.25 - 1033.5] | 804 [507.25 - 1252.25] |
| 9 days | Missing / Non-Missing | 6 / 10 | 4 / 16 |
| 10 days | Mean (SD) | 1158.38 (787.18) | 934.5 (595.1) |
| 10 days | Median [IQR] | 863 [771.5 - 1185.5] | 830 [516.5 - 1317.75] |
| 10 days | Missing / Non-Missing | 7 / 8 | 4 / 12 |
| 11 days | Mean (SD) | 1053.25 (1140.96) | 1001.33 (725.62) |
| 11 days | Median [IQR] | 625 [324.5 - 1259] | 918 [559 - 1216] |
| 11 days | Missing / Non-Missing | 5 / 8 | 6 / 9 |
| 12 days | Mean (SD) | 1409.33 (1247.82) | 868.22 (388.21) |
| 12 days | Median [IQR] | 781 [569.25 - 2240.75] | 930 [639 - 1068] |
| 12 days | Missing / Non-Missing | 5 / 6 | 4 / 9 |
| 13 days | Mean (SD) | 1014.78 (837.9) | 827.4 (593.24) |
| 13 days | Median [IQR] | 701 [451 - 880] | 671 [534 - 1140.25] |
| 13 days | Missing / Non-Missing | 1 / 9 | 3 / 10 |
| 14 days | Mean (SD) | 758.86 (462.68) | 715.5 (715.18) |
| 14 days | Median [IQR] | 698 [487.5 - 760] | 515.5 [205 - 1086.25] |
| 14 days | Missing / Non-Missing | 2 / 7 | 4 / 6 |

LDH (U/L), HCQ

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| 0 days | Mean (SD) | 295.98 (111.56) | 301.72 (112.92) |
| 0 days | Median [IQR] | 280 [220.75 - 358.75] | 290 [216 - 353.5] |
| 0 days | Missing / Non-Missing | 0 / 54 | 5 / 47 |
| 1 days | Mean (SD) | 311.1 (115.7) | 287.7 (82.56) |
| 1 days | Median [IQR] | 285.5 [243.25 - 373.25] | 279 [219 - 331] |
| 1 days | Missing / Non-Missing | 24 / 30 | 24 / 27 |
| 2 days | Mean (SD) | 309.35 (127.34) | 305.49 (102.97) |
| 2 days | Median [IQR] | 298.5 [223.25 - 342] | 300 [226 - 359] |
| 2 days | Missing / Non-Missing | 18 / 34 | 15 / 33 |
| 3 days | Mean (SD) | 320 (161.63) | 354.85 (138.37) |
| 3 days | Median [IQR] | 279 [212 - 359] | 317 [261 - 402] |
| 3 days | Missing / Non-Missing | 14 / 33 | 11 / 33 |
| 4 days | Mean (SD) | 308.56 (104.56) | 362.7 (129.91) |
| 4 days | Median [IQR] | 291 [243 - 362] | 333.5 [273.75 - 421] |
| 4 days | Missing / Non-Missing | 12 / 25 | 20 / 20 |
| 5 days | Mean (SD) | 295.29 (95.7) | 352.1 (100.19) |
| 5 days | Median [IQR] | 285 [259 - 309] | 323 [284 - 445] |
| 5 days | Missing / Non-Missing | 12 / 21 | 16 / 21 |
| 6 days | Mean (SD) | 290.63 (86.66) | 303 (81.31) |
| 6 days | Median [IQR] | 276 [244 - 305] | 278 [256 - 378.25] |
| 6 days | Missing / Non-Missing | 10 / 19 | 15 / 16 |
| 7 days | Mean (SD) | 272 (74.32) | 310.35 (101.19) |
| 7 days | Median [IQR] | 242 [223 - 319] | 290 [242.5 - 387.5] |
| 7 days | Missing / Non-Missing | 3 / 21 | 8 / 20 |
| 8 days | Mean (SD) | 279.69 (81.75) | 333.4 (114.02) |
| 8 days | Median [IQR] | 255 [232 - 315] | 285 [247 - 397] |
| 8 days | Missing / Non-Missing | 6 / 13 | 10 / 15 |
| 9 days | Mean (SD) | 274.91 (65.04) | 357.39 (151.57) |
| 9 days | Median [IQR] | 281 [236 - 295.5] | 328 [238 - 409] |
| 9 days | Missing / Non-Missing | 6 / 11 | 9 / 13 |
| 10 days | Mean (SD) | 277.22 (105.05) | 312.42 (100.25) |
| 10 days | Median [IQR] | 258 [204 - 280] | 297 [226.5 - 371] |
| 10 days | Missing / Non-Missing | 5 / 9 | 7 / 12 |
| 11 days | Mean (SD) | 232.56 (93.17) | 284.14 (106.36) |
| 11 days | Median [IQR] | 217 [179 - 269] | 252 [225 - 345.5] |
| 11 days | Missing / Non-Missing | 5 / 9 | 7 / 7 |
| 12 days | Mean (SD) | 248.17 (88.95) | 265.88 (64.21) |
| 12 days | Median [IQR] | 236.5 [180.75 - 267.5] | 255 [215 - 316.5] |
| 12 days | Missing / Non-Missing | 7 / 6 | 4 / 8 |
| 13 days | Mean (SD) | 231.14 (71.7) | 277 (56.57) |
| 13 days | Median [IQR] | 222 [182 - 270.5] | 277 [257 - 297] |
| 13 days | Missing / Non-Missing | 4 / 7 | 8 / 2 |
| 14 days | Mean (SD) | 196.8 (65.64) | 251.4 (82.96) |
| 14 days | Median [IQR] | 185 [139 - 237] | 226 [197 - 328] |
| 14 days | Missing / Non-Missing | 2 / 5 | 1 / 5 |

LDH (U/L), Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| 0 days | Mean (SD) | 295.26 (114.52) | 306.81 (162.8) |
| 0 days | Median [IQR] | 279 [209 - 369] | 274 [209 - 325] |
| 0 days | Missing / Non-Missing | 2 / 55 | 1 / 41 |
| 1 days | Mean (SD) | 302.49 (109.11) | 344.24 (183.66) |
| 1 days | Median [IQR] | 283 [239 - 392] | 314 [243 - 347] |
| 1 days | Missing / Non-Missing | 24 / 33 | 21 / 21 |
| 2 days | Mean (SD) | 298.4 (99.75) | 341.08 (167.4) |
| 2 days | Median [IQR] | 290.5 [217 - 376.75] | 326 [226.5 - 382] |
| 2 days | Missing / Non-Missing | 19 / 38 | 14 / 27 |
| 3 days | Mean (SD) | 315.41 (130.27) | 346.22 (170.07) |
| 3 days | Median [IQR] | 312.5 [207.25 - 432.5] | 321 [217.75 - 423.5] |
| 3 days | Missing / Non-Missing | 18 / 32 | 18 / 18 |
| 4 days | Mean (SD) | 340.62 (125.88) | 391.79 (193.61) |
| 4 days | Median [IQR] | 321 [240 - 412.5] | 341 [244 - 494.5] |
| 4 days | Missing / Non-Missing | 15 / 26 | 13 / 19 |
| 5 days | Mean (SD) | 328.09 (130.15) | 419.79 (195.62) |
| 5 days | Median [IQR] | 305 [230.75 - 381.25] | 307 [281.5 - 562.5] |
| 5 days | Missing / Non-Missing | 13 / 22 | 15 / 14 |
| 6 days | Mean (SD) | 310.6 (90.45) | 329.6 (174.47) |
| 6 days | Median [IQR] | 292.5 [271 - 351.75] | 277.5 [227.5 - 411.25] |
| 6 days | Missing / Non-Missing | 10 / 20 | 10 / 20 |
| 7 days | Mean (SD) | 292.53 (99.44) | 308.88 (122.33) |
| 7 days | Median [IQR] | 309 [219 - 345] | 266 [232 - 400] |
| 7 days | Missing / Non-Missing | 6 / 17 | 8 / 17 |
| 8 days | Mean (SD) | 282.58 (71.84) | 330 (107.25) |
| 8 days | Median [IQR] | 285.5 [252.75 - 309.25] | 365 [227.5 - 390.5] |
| 8 days | Missing / Non-Missing | 8 / 12 | 12 / 11 |
| 9 days | Mean (SD) | 295.6 (70.32) | 305.89 (114.5) |
| 9 days | Median [IQR] | 296.5 [254 - 340.75] | 326 [207 - 384] |
| 9 days | Missing / Non-Missing | 6 / 10 | 11 / 9 |
| 10 days | Mean (SD) | 254.88 (71.61) | 289.22 (109.35) |
| 10 days | Median [IQR] | 239.5 [202.25 - 307.25] | 348 [200 - 378] |
| 10 days | Missing / Non-Missing | 7 / 8 | 7 / 9 |
| 11 days | Mean (SD) | 238.3 (89.19) | 306.6 (113.87) |
| 11 days | Median [IQR] | 253 [162.25 - 272] | 349 [269 - 360] |
| 11 days | Missing / Non-Missing | 3 / 10 | 10 / 5 |
| 12 days | Mean (SD) | 277.14 (96.9) | 305.43 (123.29) |
| 12 days | Median [IQR] | 269 [229 - 283.5] | 361 [223 - 365.5] |
| 12 days | Missing / Non-Missing | 4 / 7 | 6 / 7 |
| 13 days | Mean (SD) | 228.57 (69.44) | 287.43 (144.79) |
| 13 days | Median [IQR] | 251 [172 - 263.5] | 231 [169.5 - 410] |
| 13 days | Missing / Non-Missing | 3 / 7 | 6 / 7 |
| 14 days | Mean (SD) | 238.86 (76.46) | 292.57 (142.64) |
| 14 days | Median [IQR] | 254 [192 - 273.5] | 294 [160.5 - 404] |
| 14 days | Missing / Non-Missing | 2 / 7 | 3 / 7 |

Lymphocytes (x10^9/L), HCQ

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| 0 days | Mean (SD) | 1.14 (0.55) | 1.12 (0.43) |
| 0 days | Median [IQR] | 1.1 [0.8 - 1.48] | 1.1 [0.8 - 1.4] |
| 0 days | Missing / Non-Missing | 0 / 54 | 6 / 46 |
| 1 days | Mean (SD) | 1.02 (0.45) | 1.34 (0.56) |
| 1 days | Median [IQR] | 0.95 [0.7 - 1.38] | 1.25 [0.95 - 1.6] |
| 1 days | Missing / Non-Missing | 20 / 34 | 15 / 36 |
| 2 days | Mean (SD) | 1.21 (0.65) | 1.35 (0.5) |
| 2 days | Median [IQR] | 1.1 [0.73 - 1.68] | 1.5 [0.9 - 1.7] |
| 2 days | Missing / Non-Missing | 14 / 38 | 11 / 37 |
| 3 days | Mean (SD) | 1.16 (0.63) | 1.32 (0.53) |
| 3 days | Median [IQR] | 1 [0.7 - 1.6] | 1.2 [0.9 - 1.65] |
| 3 days | Missing / Non-Missing | 13 / 34 | 9 / 35 |
| 4 days | Mean (SD) | 1.27 (0.76) | 1.31 (0.51) |
| 4 days | Median [IQR] | 1.1 [0.6 - 1.65] | 1.4 [0.9 - 1.6] |
| 4 days | Missing / Non-Missing | 10 / 27 | 19 / 21 |
| 5 days | Mean (SD) | 1.26 (0.71) | 1.39 (0.63) |
| 5 days | Median [IQR] | 1.1 [0.8 - 1.65] | 1.2 [0.9 - 1.8] |
| 5 days | Missing / Non-Missing | 10 / 23 | 16 / 21 |
| 6 days | Mean (SD) | 1.13 (0.68) | 1.47 (0.61) |
| 6 days | Median [IQR] | 1 [0.6 - 1.3] | 1.5 [1.05 - 1.83] |
| 6 days | Missing / Non-Missing | 5 / 24 | 15 / 16 |
| 7 days | Mean (SD) | 1.33 (0.62) | 1.51 (0.55) |
| 7 days | Median [IQR] | 1.2 [0.95 - 1.78] | 1.5 [1.3 - 1.9] |
| 7 days | Missing / Non-Missing | 2 / 22 | 9 / 19 |
| 8 days | Mean (SD) | 1.87 (1.97) | 1.68 (0.57) |
| 8 days | Median [IQR] | 1.5 [0.8 - 2.05] | 1.5 [1.28 - 2.03] |
| 8 days | Missing / Non-Missing | 4 / 15 | 9 / 16 |
| 9 days | Mean (SD) | 1.28 (0.84) | 1.77 (0.66) |
| 9 days | Median [IQR] | 0.9 [0.7 - 1.8] | 1.9 [1.25 - 2.2] |
| 9 days | Missing / Non-Missing | 4 / 13 | 11 / 11 |
| 10 days | Mean (SD) | 1.49 (0.86) | 2.09 (0.62) |
| 10 days | Median [IQR] | 1.45 [0.78 - 2.03] | 2 [1.9 - 2.6] |
| 10 days | Missing / Non-Missing | 2 / 12 | 10 / 9 |
| 11 days | Mean (SD) | 1.41 (0.67) | 2 (0.87) |
| 11 days | Median [IQR] | 1.55 [0.8 - 1.98] | 2 [1.65 - 2.45] |
| 11 days | Missing / Non-Missing | 4 / 10 | 7 / 7 |
| 12 days | Mean (SD) | 1.54 (1) | 2.48 (1.04) |
| 12 days | Median [IQR] | 1.2 [0.75 - 2.1] | 2.55 [2.05 - 3.28] |
| 12 days | Missing / Non-Missing | 6 / 7 | 4 / 8 |
| 13 days | Mean (SD) | 1.8 (0.93) | 1.93 (1.4) |
| 13 days | Median [IQR] | 1.8 [1.05 - 2.55] | 2 [1.25 - 2.65] |
| 13 days | Missing / Non-Missing | 4 / 7 | 7 / 3 |
| 14 days | Mean (SD) | 1.67 (0.94) | 2.12 (1.26) |
| 14 days | Median [IQR] | 1.85 [0.8 - 2.3] | 2.3 [1.1 - 3] |
| 14 days | Missing / Non-Missing | 1 / 6 | 1 / 5 |

Lymphocytes (x10^9/L), Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| 0 days | Mean (SD) | 1.25 (0.91) | 1.21 (0.62) |
| 0 days | Median [IQR] | 1.1 [0.8 - 1.3] | 1.1 [0.7 - 1.5] |
| 0 days | Missing / Non-Missing | 2 / 55 | 1 / 41 |
| 1 days | Mean (SD) | 1.13 (0.37) | 1.1 (0.56) |
| 1 days | Median [IQR] | 1.1 [0.9 - 1.4] | 1 [0.7 - 1.3] |
| 1 days | Missing / Non-Missing | 20 / 37 | 19 / 23 |
| 2 days | Mean (SD) | 1.3 (0.57) | 1.3 (0.61) |
| 2 days | Median [IQR] | 1.1 [1 - 1.6] | 1.1 [0.9 - 1.6] |
| 2 days | Missing / Non-Missing | 10 / 47 | 12 / 29 |
| 3 days | Mean (SD) | 1.36 (0.68) | 1.23 (0.54) |
| 3 days | Median [IQR] | 1.3 [0.9 - 1.6] | 1.2 [0.9 - 1.5] |
| 3 days | Missing / Non-Missing | 15 / 35 | 14 / 22 |
| 4 days | Mean (SD) | 1.44 (0.81) | 1.16 (0.56) |
| 4 days | Median [IQR] | 1.3 [1.03 - 1.68] | 1 [0.7 - 1.5] |
| 4 days | Missing / Non-Missing | 11 / 30 | 7 / 25 |
| 5 days | Mean (SD) | 1.54 (0.81) | 1.2 (0.5) |
| 5 days | Median [IQR] | 1.3 [1.1 - 1.85] | 1.2 [0.75 - 1.55] |
| 5 days | Missing / Non-Missing | 9 / 26 | 10 / 19 |
| 6 days | Mean (SD) | 1.47 (0.84) | 1.47 (0.62) |
| 6 days | Median [IQR] | 1.25 [1.08 - 1.53] | 1.4 [1.1 - 2.03] |
| 6 days | Missing / Non-Missing | 6 / 24 | 10 / 20 |
| 7 days | Mean (SD) | 1.33 (0.37) | 1.32 (0.68) |
| 7 days | Median [IQR] | 1.3 [1.2 - 1.43] | 1.2 [0.95 - 1.6] |
| 7 days | Missing / Non-Missing | 3 / 20 | 7 / 18 |
| 8 days | Mean (SD) | 1.49 (0.44) | 1.6 (0.94) |
| 8 days | Median [IQR] | 1.55 [1.15 - 1.8] | 1.6 [1.1 - 1.75] |
| 8 days | Missing / Non-Missing | 6 / 14 | 8 / 15 |
| 9 days | Mean (SD) | 1.44 (0.44) | 1.47 (0.7) |
| 9 days | Median [IQR] | 1.3 [1.1 - 1.8] | 1.35 [1.1 - 1.6] |
| 9 days | Missing / Non-Missing | 5 / 11 | 6 / 14 |
| 10 days | Mean (SD) | 1.68 (0.64) | 1.59 (0.64) |
| 10 days | Median [IQR] | 1.75 [1.18 - 2] | 1.5 [1.3 - 1.9] |
| 10 days | Missing / Non-Missing | 3 / 12 | 5 / 11 |
| 11 days | Mean (SD) | 1.63 (0.49) | 1.58 (0.61) |
| 11 days | Median [IQR] | 1.8 [1.23 - 1.98] | 1.6 [1.48 - 1.93] |
| 11 days | Missing / Non-Missing | 3 / 10 | 7 / 8 |
| 12 days | Mean (SD) | 1.93 (0.95) | 1.52 (0.68) |
| 12 days | Median [IQR] | 2 [1.15 - 2.55] | 1.5 [1.35 - 1.65] |
| 12 days | Missing / Non-Missing | 4 / 7 | 6 / 7 |
| 13 days | Mean (SD) | 2.07 (0.66) | 1.8 (0.74) |
| 13 days | Median [IQR] | 2.1 [1.65 - 2.5] | 1.8 [1.48 - 2.03] |
| 13 days | Missing / Non-Missing | 3 / 7 | 5 / 8 |
| 14 days | Mean (SD) | 1.75 (0.69) | 1.63 (0.66) |
| 14 days | Median [IQR] | 1.7 [1.28 - 2.3] | 1.75 [1.25 - 2.13] |
| 14 days | Missing / Non-Missing | 1 / 8 | 2 / 8 |

Neutrophils (x10^9/L), HCQ

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| 0 days | Mean (SD) | 5.55 (3.03) | 5.11 (3.29) |
| 0 days | Median [IQR] | 4.8 [3 - 7.4] | 4.55 [3.05 - 6.4] |
| 0 days | Missing / Non-Missing | 1 / 53 | 6 / 46 |
| 1 days | Mean (SD) | 5.41 (3.17) | 4.96 (4.11) |
| 1 days | Median [IQR] | 4.75 [3.4 - 6.23] | 3.85 [2.75 - 5.58] |
| 1 days | Missing / Non-Missing | 20 / 34 | 15 / 36 |
| 2 days | Mean (SD) | 5.63 (3.54) | 4.79 (3.2) |
| 2 days | Median [IQR] | 4.75 [3.28 - 6.85] | 3.65 [2.7 - 6.15] |
| 2 days | Missing / Non-Missing | 14 / 38 | 10 / 38 |
| 3 days | Mean (SD) | 5.37 (3.37) | 5.02 (3.17) |
| 3 days | Median [IQR] | 4.4 [2.93 - 6.78] | 3.8 [3 - 6.95] |
| 3 days | Missing / Non-Missing | 13 / 34 | 9 / 35 |
| 4 days | Mean (SD) | 5.59 (3.14) | 5.05 (3.26) |
| 4 days | Median [IQR] | 4.7 [3.7 - 6.75] | 4 [3 - 6.6] |
| 4 days | Missing / Non-Missing | 10 / 27 | 19 / 21 |
| 5 days | Mean (SD) | 5.23 (2.99) | 6.03 (3.15) |
| 5 days | Median [IQR] | 4.7 [3.5 - 5.95] | 5.3 [4.1 - 8.3] |
| 5 days | Missing / Non-Missing | 10 / 23 | 16 / 21 |
| 6 days | Mean (SD) | 6.06 (3.72) | 5.69 (2.87) |
| 6 days | Median [IQR] | 4.8 [4.08 - 6.93] | 4.65 [3.93 - 7.55] |
| 6 days | Missing / Non-Missing | 5 / 24 | 15 / 16 |
| 7 days | Mean (SD) | 6.65 (3.54) | 6.21 (2.48) |
| 7 days | Median [IQR] | 5.6 [4.2 - 8.25] | 5.6 [4.05 - 8.05] |
| 7 days | Missing / Non-Missing | 2 / 22 | 9 / 19 |
| 8 days | Mean (SD) | 6.15 (3.43) | 6.98 (2.97) |
| 8 days | Median [IQR] | 5.8 [4 - 7.3] | 6.15 [4.63 - 8.65] |
| 8 days | Missing / Non-Missing | 4 / 15 | 9 / 16 |
| 9 days | Mean (SD) | 6.91 (4.47) | 6.86 (2.43) |
| 9 days | Median [IQR] | 5.9 [3.9 - 7.7] | 5.4 [4.9 - 8.45] |
| 9 days | Missing / Non-Missing | 4 / 13 | 11 / 11 |
| 10 days | Mean (SD) | 7.6 (3.93) | 5.79 (3.5) |
| 10 days | Median [IQR] | 6.75 [5.03 - 8.6] | 4.9 [4.1 - 6.3] |
| 10 days | Missing / Non-Missing | 2 / 12 | 10 / 9 |
| 11 days | Mean (SD) | 6.22 (2.23) | 8.1 (4.24) |
| 11 days | Median [IQR] | 6.8 [4.7 - 7.25] | 7.45 [4.63 - 10.48] |
| 11 days | Missing / Non-Missing | 4 / 10 | 6 / 8 |
| 12 days | Mean (SD) | 9.62 (4) | 7.15 (4.5) |
| 12 days | Median [IQR] | 10.7 [6.25 - 11] | 5.15 [3.6 - 11.5] |
| 12 days | Missing / Non-Missing | 6 / 7 | 4 / 8 |
| 13 days | Mean (SD) | 7.73 (2.65) | 11.33 (1.27) |
| 13 days | Median [IQR] | 6.9 [5.65 - 9.65] | 11.1 [10.65 - 11.9] |
| 13 days | Missing / Non-Missing | 4 / 7 | 7 / 3 |
| 14 days | Mean (SD) | 6.27 (2.48) | 7 (2.81) |
| 14 days | Median [IQR] | 5.35 [5.05 - 8.13] | 6.5 [6.5 - 7.8] |
| 14 days | Missing / Non-Missing | 1 / 6 | 1 / 5 |

Neutrophils (x10^9/L), Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| 0 days | Mean (SD) | 4.76 (2.91) | 4.82 (2.41) |
| 0 days | Median [IQR] | 3.8 [2.45 - 6.65] | 3.9 [3.2 - 5.6] |
| 0 days | Missing / Non-Missing | 2 / 55 | 1 / 41 |
| 1 days | Mean (SD) | 5.13 (2.98) | 4.81 (3.21) |
| 1 days | Median [IQR] | 4.6 [2.4 - 7.4] | 3.8 [3.15 - 5.45] |
| 1 days | Missing / Non-Missing | 20 / 37 | 19 / 23 |
| 2 days | Mean (SD) | 5.07 (3.21) | 5.2 (3.14) |
| 2 days | Median [IQR] | 4.1 [2.9 - 7.2] | 4.6 [2.7 - 6.4] |
| 2 days | Missing / Non-Missing | 10 / 47 | 12 / 29 |
| 3 days | Mean (SD) | 5.08 (3.17) | 5.57 (3.67) |
| 3 days | Median [IQR] | 3.8 [3.1 - 6.65] | 4.8 [3.23 - 6.83] |
| 3 days | Missing / Non-Missing | 15 / 35 | 14 / 22 |
| 4 days | Mean (SD) | 5.43 (2.69) | 6.18 (5.08) |
| 4 days | Median [IQR] | 5 [3.95 - 6.55] | 4.75 [3.48 - 7.68] |
| 4 days | Missing / Non-Missing | 10 / 31 | 8 / 24 |
| 5 days | Mean (SD) | 4.74 (2.03) | 6.28 (4.17) |
| 5 days | Median [IQR] | 4.8 [3.4 - 5.5] | 5.1 [4.1 - 7.4] |
| 5 days | Missing / Non-Missing | 10 / 25 | 10 / 19 |
| 6 days | Mean (SD) | 5.81 (3.23) | 5.94 (4.04) |
| 6 days | Median [IQR] | 4.8 [3.95 - 6.5] | 4.9 [3.4 - 7.35] |
| 6 days | Missing / Non-Missing | 6 / 24 | 10 / 20 |
| 7 days | Mean (SD) | 5.67 (2.91) | 6.03 (3.88) |
| 7 days | Median [IQR] | 4.9 [3.9 - 5.98] | 5 [2.98 - 7.85] |
| 7 days | Missing / Non-Missing | 3 / 20 | 7 / 18 |
| 8 days | Mean (SD) | 6.25 (3.14) | 7.32 (4.05) |
| 8 days | Median [IQR] | 5.4 [4.25 - 7.15] | 6 [5.05 - 8.35] |
| 8 days | Missing / Non-Missing | 6 / 14 | 8 / 15 |
| 9 days | Mean (SD) | 7.18 (4.39) | 7.26 (3.57) |
| 9 days | Median [IQR] | 6.1 [4.2 - 7.35] | 7.1 [5.48 - 8.93] |
| 9 days | Missing / Non-Missing | 5 / 11 | 6 / 14 |
| 10 days | Mean (SD) | 6.87 (4) | 7.92 (3.52) |
| 10 days | Median [IQR] | 5.55 [4.28 - 7.73] | 7.2 [5.75 - 10.2] |
| 10 days | Missing / Non-Missing | 3 / 12 | 5 / 11 |
| 11 days | Mean (SD) | 6.03 (1.95) | 7.29 (3.05) |
| 11 days | Median [IQR] | 5.7 [4.28 - 7.25] | 7.65 [5.15 - 9.73] |
| 11 days | Missing / Non-Missing | 3 / 10 | 7 / 8 |
| 12 days | Mean (SD) | 8.94 (3.73) | 8.2 (2.58) |
| 12 days | Median [IQR] | 7.5 [6.25 - 10.78] | 7.7 [6.2 - 10.1] |
| 12 days | Missing / Non-Missing | 3 / 8 | 6 / 7 |
| 13 days | Mean (SD) | 7.82 (5.5) | 8.47 (3.64) |
| 13 days | Median [IQR] | 5.4 [5.05 - 8.8] | 8 [5.85 - 11.6] |
| 13 days | Missing / Non-Missing | 3 / 7 | 6 / 7 |
| 14 days | Mean (SD) | 8.76 (3.2) | 7.02 (3.72) |
| 14 days | Median [IQR] | 8.5 [6.18 - 10.25] | 6.9 [4.7 - 7.9] |
| 14 days | Missing / Non-Missing | 1 / 8 | 3 / 7 |













Procalcitonin (µg/L), HCQ

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| 0 days | Mean (SD) | 0.45 (1.24) | 0.44 (1.76) |
| 0 days | Median [IQR] | 0.15 [0.1 - 0.25] | 0.13 [0.1 - 0.2] |
| 0 days | Missing / Non-Missing | 19 / 35 | 14 / 38 |
| 1 days | Mean (SD) | 0.92 (2.36) | 1.76 (5.69) |
| 1 days | Median [IQR] | 0.11 [0.1 - 0.2] | 0.2 [0.13 - 0.25] |
| 1 days | Missing / Non-Missing | 32 / 22 | 38 / 13 |
| 2 days | Mean (SD) | 0.86 (2.14) | 1.67 (6.01) |
| 2 days | Median [IQR] | 0.14 [0.1 - 0.35] | 0.2 [0.1 - 0.31] |
| 2 days | Missing / Non-Missing | 28 / 24 | 25 / 23 |
| 3 days | Mean (SD) | 0.21 (0.25) | 1.02 (3.59) |
| 3 days | Median [IQR] | 0.1 [0.1 - 0.2] | 0.18 [0.1 - 0.29] |
| 3 days | Missing / Non-Missing | 24 / 23 | 20 / 24 |
| 4 days | Mean (SD) | 0.39 (0.79) | 1.29 (2.82) |
| 4 days | Median [IQR] | 0.14 [0.1 - 0.21] | 0.18 [0.14 - 0.55] |
| 4 days | Missing / Non-Missing | 20 / 17 | 31 / 9 |
| 5 days | Mean (SD) | 0.41 (0.6) | 0.57 (1.2) |
| 5 days | Median [IQR] | 0.14 [0.1 - 0.22] | 0.16 [0.1 - 0.31] |
| 5 days | Missing / Non-Missing | 19 / 14 | 25 / 12 |
| 6 days | Mean (SD) | 0.56 (1.16) | 0.41 (0.77) |
| 6 days | Median [IQR] | 0.1 [0.1 - 0.19] | 0.1 [0.1 - 0.35] |
| 6 days | Missing / Non-Missing | 18 / 11 | 21 / 10 |
| 7 days | Mean (SD) | 0.16 (0.14) | 0.32 (0.49) |
| 7 days | Median [IQR] | 0.1 [0.1 - 0.18] | 0.13 [0.1 - 0.34] |
| 7 days | Missing / Non-Missing | 10 / 14 | 14 / 14 |
| 8 days | Mean (SD) | 0.22 (0.21) | 0.27 (0.31) |
| 8 days | Median [IQR] | 0.13 [0.1 - 0.21] | 0.1 [0.1 - 0.32] |
| 8 days | Missing / Non-Missing | 10 / 9 | 13 / 12 |
| 9 days | Mean (SD) | 0.42 (0.56) | 0.34 (0.4) |
| 9 days | Median [IQR] | 0.19 [0.1 - 0.4] | 0.13 [0.09 - 0.51] |
| 9 days | Missing / Non-Missing | 9 / 8 | 14 / 8 |
| 10 days | Mean (SD) | 0.22 (0.19) | 0.22 (0.2) |
| 10 days | Median [IQR] | 0.1 [0.1 - 0.27] | 0.13 [0.09 - 0.34] |
| 10 days | Missing / Non-Missing | 7 / 7 | 13 / 6 |
| 11 days | Mean (SD) | 0.15 (0.17) | 1.4 (2.35) |
| 11 days | Median [IQR] | 0.1 [0.09 - 0.1] | 0.33 [0.23 - 1.13] |
| 11 days | Missing / Non-Missing | 8 / 6 | 8 / 6 |
| 12 days | Mean (SD) | 0.47 (0.75) | 0.35 (0.48) |
| 12 days | Median [IQR] | 0.1 [0.1 - 0.48] | 0.19 [0.06 - 0.3] |
| 12 days | Missing / Non-Missing | 9 / 4 | 6 / 6 |
| 13 days | Mean (SD) | 0.14 (0.09) | 0.49 (0.45) |
| 13 days | Median [IQR] | 0.1 [0.1 - 0.1] | 0.49 [0.33 - 0.64] |
| 13 days | Missing / Non-Missing | 6 / 5 | 8 / 2 |
| 14 days | Mean (SD) | 0.1 (0.05) | 0.21 (0.13) |
| 14 days | Median [IQR] | 0.1 [0.08 - 0.13] | 0.17 [0.13 - 0.24] |
| 14 days | Missing / Non-Missing | 4 / 3 | 2 / 4 |

Procalcitonin (µg/L), Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Days since randomisation | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| 0 days | Mean (SD) | 0.21 (0.21) | 0.33 (0.39) |
| 0 days | Median [IQR] | 0.1 [0.1 - 0.19] | 0.15 [0.1 - 0.39] |
| 0 days | Missing / Non-Missing | 23 / 34 | 12 / 30 |
| 1 days | Mean (SD) | 0.33 (0.45) | 0.71 (1.61) |
| 1 days | Median [IQR] | 0.12 [0.1 - 0.3] | 0.16 [0.1 - 0.38] |
| 1 days | Missing / Non-Missing | 38 / 19 | 31 / 11 |
| 2 days | Mean (SD) | 0.24 (0.28) | 0.5 (0.72) |
| 2 days | Median [IQR] | 0.12 [0.1 - 0.3] | 0.2 [0.1 - 0.46] |
| 2 days | Missing / Non-Missing | 30 / 27 | 18 / 23 |
| 3 days | Mean (SD) | 0.21 (0.23) | 0.23 (0.25) |
| 3 days | Median [IQR] | 0.11 [0.1 - 0.2] | 0.1 [0.1 - 0.21] |
| 3 days | Missing / Non-Missing | 29 / 21 | 21 / 15 |
| 4 days | Mean (SD) | 0.29 (0.39) | 1.42 (3.97) |
| 4 days | Median [IQR] | 0.2 [0.1 - 0.22] | 0.19 [0.1 - 0.52] |
| 4 days | Missing / Non-Missing | 25 / 16 | 19 / 13 |
| 5 days | Mean (SD) | 0.34 (0.53) | 1.7 (4.19) |
| 5 days | Median [IQR] | 0.11 [0.1 - 0.22] | 0.36 [0.17 - 0.65] |
| 5 days | Missing / Non-Missing | 25 / 10 | 19 / 10 |
| 6 days | Mean (SD) | 0.26 (0.33) | 0.84 (2.38) |
| 6 days | Median [IQR] | 0.1 [0.1 - 0.22] | 0.15 [0.12 - 0.29] |
| 6 days | Missing / Non-Missing | 17 / 13 | 15 / 15 |
| 7 days | Mean (SD) | 0.12 (0.04) | 0.29 (0.24) |
| 7 days | Median [IQR] | 0.1 [0.1 - 0.12] | 0.16 [0.11 - 0.53] |
| 7 days | Missing / Non-Missing | 13 / 10 | 13 / 12 |
| 8 days | Mean (SD) | 0.14 (0.1) | 0.63 (1.1) |
| 8 days | Median [IQR] | 0.1 [0.1 - 0.13] | 0.19 [0.1 - 0.51] |
| 8 days | Missing / Non-Missing | 11 / 9 | 15 / 8 |
| 9 days | Mean (SD) | 0.17 (0.16) | 0.44 (0.68) |
| 9 days | Median [IQR] | 0.1 [0.1 - 0.12] | 0.16 [0.1 - 0.36] |
| 9 days | Missing / Non-Missing | 10 / 6 | 11 / 9 |
| 10 days | Mean (SD) | 0.1 (0) | 0.36 (0.51) |
| 10 days | Median [IQR] | 0.1 [0.1 - 0.1] | 0.17 [0.1 - 0.3] |
| 10 days | Missing / Non-Missing | 12 / 3 | 8 / 8 |
| 11 days | Mean (SD) | 0.12 (0.1) | 0.29 (0.24) |
| 11 days | Median [IQR] | 0.1 [0.1 - 0.1] | 0.15 [0.11 - 0.5] |
| 11 days | Missing / Non-Missing | 8 / 5 | 10 / 5 |
| 12 days | Mean (SD) | 0.1 (0) | 0.2 (0.2) |
| 12 days | Median [IQR] | 0.1 [0.1 - 0.1] | 0.1 [0.1 - 0.17] |
| 12 days | Missing / Non-Missing | 9 / 2 | 6 / 7 |
| 13 days | Mean (SD) | 0.39 (0.52) | 0.49 (0.85) |
| 13 days | Median [IQR] | 0.1 [0.1 - 0.34] | 0.16 [0.12 - 0.28] |
| 13 days | Missing / Non-Missing | 5 / 5 | 6 / 7 |
| 14 days | Mean (SD) | 0.13 (0.04) | 0.71 (0.85) |
| 14 days | Median [IQR] | 0.13 [0.11 - 0.14] | 0.4 [0.28 - 0.65] |
| 14 days | Missing / Non-Missing | 7 / 2 | 4 / 6 |

### Plots



### Efficacy estimates

CRP (mg/L), HCQ

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -14.286 | -18.866 | -9.707 | 0.000 |
| Slope 1st week by treatment | Hydroxychloroquine + SOC | -8.296 | -11.899 | -4.692 | 0.000 |
| Difference in 1st week slope | Hydroxychloroquine + SOC | 5.991 | 0.513 | 11.469 | 0.032 |
| Day 10 level by treatment | Standard of care (SOC) | 21.716 | 15.421 | 28.012 | 0.000 |
| Day 10 level by treatment | Hydroxychloroquine + SOC | 49.001 | 34.326 | 63.676 | 0.000 |
| Day 10 treatment difference | Hydroxychloroquine + SOC | 27.284 | 11.860 | 42.709 | 0.001 |

CRP (mg/L), Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -14.788 | -21.100 | -8.475 | 0.000 |
| Slope 1st week by treatment | Remdesivir + SOC | -9.522 | -14.714 | -4.331 | 0.000 |
| Difference in 1st week slope | Remdesivir + SOC | 5.265 | -2.124 | 12.655 | 0.163 |
| Day 10 level by treatment | Standard of care (SOC) | 40.123 | 25.086 | 55.160 | 0.000 |
| Day 10 level by treatment | Remdesivir + SOC | 50.192 | 29.849 | 70.536 | 0.000 |
| Day 10 treatment difference | Remdesivir + SOC | 10.069 | -12.817 | 32.956 | 0.389 |

Ferritin (µg/L), HCQ

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -31.201 | -49.910 | -12.492 | 0.001 |
| Slope 1st week by treatment | Hydroxychloroquine + SOC | 37.562 | 13.374 | 61.750 | 0.002 |
| Difference in 1st week slope | Hydroxychloroquine + SOC | 68.763 | 37.821 | 99.705 | 0.000 |
| Day 10 level by treatment | Standard of care (SOC) | 683.362 | 498.285 | 868.440 | 0.000 |
| Day 10 level by treatment | Hydroxychloroquine + SOC | 982.830 | 710.341 | 1255.319 | 0.000 |
| Day 10 treatment difference | Hydroxychloroquine + SOC | 299.467 | -7.687 | 606.622 | 0.056 |

Ferritin (µg/L), Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | 9.099 | -11.490 | 29.687 | 0.386 |
| Slope 1st week by treatment | Remdesivir + SOC | -22.015 | -41.455 | -2.575 | 0.026 |
| Difference in 1st week slope | Remdesivir + SOC | -31.113 | -59.534 | -2.693 | 0.032 |
| Day 10 level by treatment | Standard of care (SOC) | 988.203 | 701.740 | 1274.667 | 0.000 |
| Day 10 level by treatment | Remdesivir + SOC | 796.777 | 539.509 | 1054.045 | 0.000 |
| Day 10 treatment difference | Remdesivir + SOC | -191.426 | -542.255 | 159.402 | 0.285 |

LDH (U/L), HCQ

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -7.669 | -10.532 | -4.806 | 0.000 |
| Slope 1st week by treatment | Hydroxychloroquine + SOC | 1.327 | -2.017 | 4.671 | 0.437 |
| Difference in 1st week slope | Hydroxychloroquine + SOC | 8.996 | 4.606 | 13.385 | 0.000 |
| Day 10 level by treatment | Standard of care (SOC) | 214.824 | 194.295 | 235.353 | 0.000 |
| Day 10 level by treatment | Hydroxychloroquine + SOC | 277.712 | 250.522 | 304.902 | 0.000 |
| Day 10 treatment difference | Hydroxychloroquine + SOC | 62.888 | 28.942 | 96.834 | 0.000 |

LDH (U/L), Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -3.830 | -7.339 | -0.322 | 0.032 |
| Slope 1st week by treatment | Remdesivir + SOC | -7.775 | -11.772 | -3.777 | 0.000 |
| Difference in 1st week slope | Remdesivir + SOC | -3.945 | -9.242 | 1.353 | 0.144 |
| Day 10 level by treatment | Standard of care (SOC) | 239.226 | 211.600 | 266.853 | 0.000 |
| Day 10 level by treatment | Remdesivir + SOC | 236.796 | 206.091 | 267.500 | 0.000 |
| Day 10 treatment difference | Remdesivir + SOC | -2.431 | -43.392 | 38.530 | 0.907 |

Lymphocytes (x10^9/L), HCQ

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | 0.090 | 0.062 | 0.117 | 0.000 |
| Slope 1st week by treatment | Hydroxychloroquine + SOC | 0.068 | 0.040 | 0.096 | 0.000 |
| Difference in 1st week slope | Hydroxychloroquine + SOC | -0.022 | -0.061 | 0.017 | 0.273 |
| Day 10 level by treatment | Standard of care (SOC) | 1.985 | 1.702 | 2.269 | 0.000 |
| Day 10 level by treatment | Hydroxychloroquine + SOC | 1.885 | 1.609 | 2.162 | 0.000 |
| Day 10 treatment difference | Hydroxychloroquine + SOC | -0.100 | -0.486 | 0.286 | 0.611 |

Lymphocytes (x10^9/L), Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | 0.071 | 0.046 | 0.095 | 0.000 |
| Slope 1st week by treatment | Remdesivir + SOC | 0.063 | 0.039 | 0.087 | 0.000 |
| Difference in 1st week slope | Remdesivir + SOC | -0.008 | -0.042 | 0.026 | 0.657 |
| Day 10 level by treatment | Standard of care (SOC) | 1.951 | 1.708 | 2.194 | 0.000 |
| Day 10 level by treatment | Remdesivir + SOC | 1.697 | 1.462 | 1.932 | 0.000 |
| Day 10 treatment difference | Remdesivir + SOC | -0.254 | -0.585 | 0.076 | 0.132 |

Neutrophils (x10^9/L), HCQ

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -0.063 | -0.154 | 0.028 | 0.174 |
| Slope 1st week by treatment | Hydroxychloroquine + SOC | 0.116 | 0.017 | 0.216 | 0.022 |
| Difference in 1st week slope | Hydroxychloroquine + SOC | 0.179 | 0.045 | 0.314 | 0.009 |
| Day 10 level by treatment | Standard of care (SOC) | 5.423 | 4.598 | 6.248 | 0.000 |
| Day 10 level by treatment | Hydroxychloroquine + SOC | 6.299 | 5.288 | 7.310 | 0.000 |
| Day 10 treatment difference | Hydroxychloroquine + SOC | 0.876 | -0.413 | 2.164 | 0.183 |

Neutrophils (x10^9/L), Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -0.017 | -0.106 | 0.071 | 0.700 |
| Slope 1st week by treatment | Remdesivir + SOC | 0.062 | -0.044 | 0.167 | 0.253 |
| Difference in 1st week slope | Remdesivir + SOC | 0.079 | -0.058 | 0.216 | 0.260 |
| Day 10 level by treatment | Standard of care (SOC) | 5.516 | 4.662 | 6.370 | 0.000 |
| Day 10 level by treatment | Remdesivir + SOC | 5.946 | 4.908 | 6.983 | 0.000 |
| Day 10 treatment difference | Remdesivir + SOC | 0.429 | -0.892 | 1.751 | 0.524 |

Procalcitonin (µg/L), HCQ

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -0.032 | -0.050 | -0.014 | 0.000 |
| Slope 1st week by treatment | Hydroxychloroquine + SOC | -0.019 | -0.037 | -0.001 | 0.039 |
| Difference in 1st week slope | Hydroxychloroquine + SOC | 0.013 | -0.012 | 0.037 | 0.316 |
| Day 10 level by treatment | Standard of care (SOC) | 0.152 | 0.093 | 0.210 | 0.000 |
| Day 10 level by treatment | Hydroxychloroquine + SOC | 0.246 | 0.149 | 0.342 | 0.000 |
| Day 10 treatment difference | Hydroxychloroquine + SOC | 0.094 | -0.013 | 0.202 | 0.086 |

Procalcitonin (µg/L), Remdesivir

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Estimator | Treatment | Estimate | Lower 95% CL | Upper 95% CL | P-value |
| Slope 1st week by treatment | Standard of care (SOC) | -0.028 | -0.042 | -0.014 | 0.000 |
| Slope 1st week by treatment | Remdesivir + SOC | -0.021 | -0.037 | -0.005 | 0.009 |
| Difference in 1st week slope | Remdesivir + SOC | 0.007 | -0.014 | 0.027 | 0.520 |
| Day 10 level by treatment | Standard of care (SOC) | 0.163 | 0.107 | 0.218 | 0.000 |
| Day 10 level by treatment | Remdesivir + SOC | 0.243 | 0.160 | 0.326 | 0.000 |
| Day 10 treatment difference | Remdesivir + SOC | 0.081 | -0.016 | 0.177 | 0.102 |

## SARS-CoV2 antibodies at day 90

### Descriptives

Hydroxychloroquine

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | Statistic | Standard of care (SOC) | Hydroxychloroquine + SOC |
| Receptor-bindind domain | Mean (SD) | 59.9 (42.4) | 55.3 (46.5) |
|  | Median (IQR) | 62.5 (26.4 - 97.3) | 51.1 (15.9 - 89.2) |
| Normalised receptor-binding domain | Mean (SD) | 17.8 (10.7) | 15.3 (12) |
|  | Median (IQR) | 16.2 (10.4 - 24.9) | 12.3 (6.3 - 22.9) |
| log10 ACE2 receptor-binding domain | Mean (SD) | 1.26 (0.68) | 1.31 (0.55) |
|  | Median (IQR) | 1.32 (0.79 - 1.75) | 1.39 (0.92 - 1.65) |

Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | Statistic | Standard of care (SOC) | Remdesivir + SOC |
| Receptor-bindind domain | Mean (SD) | 64.2 (39) | 52.3 (37.7) |
|  | Median (IQR) | 64 (31.2 - 96.6) | 51.9 (21.2 - 75.5) |
| Normalised receptor-binding domain | Mean (SD) | 19.1 (10.3) | 16.7 (10) |
|  | Median (IQR) | 18.2 (12 - 24.6) | 17.2 (9.7 - 24.6) |
| log10 ACE2 receptor-binding domain | Mean (SD) | 1.19 (0.61) | 1 (0.78) |
|  | Median (IQR) | 1.21 (0.89 - 1.64) | 0.99 (0.29 - 1.54) |

### Marginal probability estimates by treatment group and difference

Hydroxychloroquine

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | Standard of care (SOC) | Hydroxychloroquine + SOC | Estimated marginal treatment effect |
| Receptor-bindind domain | 59.9 (46.6 to 73.2) | 55.3 (41.6 to 68.9) | -4.6 (-23.7 to 14.4) |
| Normalised receptor-binding domain | 17.8 (14.4 to 21.2) | 15.3 (11.9 to 18.8) | -2.5 (-7.4 to 2.3) |
| log10 ACE2 receptor-binding domain | 1.26 (1.08 to 1.45) | 1.31 (1.12 to 1.5) | 0.05 (-0.21 to 0.32) |

Estimates are presented with 95% confidence limits



Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | Standard of care (SOC) | Remdesivir + SOC | Estimated marginal treatment effect |
| Receptor-bindind domain | 64.2 (53 to 75.4) | 52.3 (38.7 to 65.8) | -11.9 (-29.5 to 5.6) |
| Normalised receptor-binding domain | 19.1 (16.2 to 22.1) | 16.7 (13.1 to 20.3) | -2.4 (-7 to 2.3) |
| log10 ACE2 receptor-binding domain | 1.19 (1 to 1.39) | 1 (0.76 to 1.24) | -0.19 (-0.5 to 0.12) |



Estimates are presented with 95% confidence limits

## Time to last discharge

### HCQ



### Remdesivir



# Adverse Events

## AE Summary

Summary of Adverse Events

|  |  |  |  |
| --- | --- | --- | --- |
| Parameter | SOC (N=87) | SOC + HCQ (N=52) | SOC + Remdesivir (N=42) |
| Number of AEs | [31] 22 (25.3%) | [26] 17 (32.7%) | [36] 19 (45.2%) |
| Number of patients with any AEs? | 22 (25.3%) | 17 (32.7%) | 19 (45.2%) |
| Number of patients with one AE | 18 (20.7%) | 12 (23.1%) | 10 (23.8%) |
| Number of patients with two AE | 1 (1.1%) | 1 (1.9%) | 4 (9.5%) |
| Number of patients with three or more AEs | 3 (3.4%) | 4 (7.7%) | 5 (11.9%) |
| Number of SAEs | [15] 11 (12.6%) | [11] 9 (17.3%) | [19] 11 (26.2%) |
| Number of patients with any SAEs? | 11 (12.6%) | 9 (17.3%) | 11 (26.2%) |

The numbers are [Number of events] Number of patients (percentage of patients), or Number of patients (percentage of patients)

## By System Organ Class and Preferred Term

Adverse Events by System Organ Class and Preferred term

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| System Organ Class | Preferred Term | SOC (N=87) | SOC + HCQ (N=52) | SOC + Remdesivir (N=42) |
| Blood and lymphatic system disorders | #Total |  |  | [2] 1 (2.4%) |
|  | Leukopenia |  |  | [1] 1 (2.4%) |
|  | Thrombocytopenia |  |  | [1] 1 (2.4%) |
| Cardiac disorders | #Total | [1] 1 (1.1%) | [2] 1 (1.9%) | [1] 1 (2.4%) |
|  | Arrhythmia |  | [2] 1 (1.9%) |  |
|  | Ventricular tachycardia | [1] 1 (1.1%) |  | [1] 1 (2.4%) |
| Gastrointestinal disorders | #Total | [5] 5 (5.7%) | [4] 3 (5.8%) | [1] 1 (2.4%) |
|  | Abdominal pain | [1] 1 (1.1%) |  |  |
|  | Diarrhoea |  | [1] 1 (1.9%) |  |
|  | Diarrhoea haemorrhagic |  | [1] 1 (1.9%) |  |
|  | Gastrooesophageal reflux disease | [1] 1 (1.1%) |  |  |
|  | Intestinal pseudo-obstruction |  |  | [1] 1 (2.4%) |
|  | Nausea | [1] 1 (1.1%) | [1] 1 (1.9%) |  |
|  | Pancreatic failure | [1] 1 (1.1%) |  |  |
|  | Vomiting | [1] 1 (1.1%) | [1] 1 (1.9%) |  |
| General disorders and administration site conditions | #Total | [2] 2 (2.3%) | [1] 1 (1.9%) | [2] 2 (4.8%) |
|  | Chest pain |  |  | [1] 1 (2.4%) |
|  | General physical health deterioration | [1] 1 (1.1%) |  |  |
|  | Medical device site reaction |  |  | [1] 1 (2.4%) |
|  | Pyrexia | [1] 1 (1.1%) | [1] 1 (1.9%) |  |
| Hepatobiliary disorders | #Total | [1] 1 (1.1%) |  |  |
|  | Cholecystitis | [1] 1 (1.1%) |  |  |
| Infections and infestations | #Total | [1] 1 (1.1%) | [1] 1 (1.9%) | [3] 3 (7.1%) |
|  | COVID-19 | [1] 1 (1.1%) |  |  |
|  | Infection |  |  | [1] 1 (2.4%) |
|  | Pneumonia bacterial |  |  | [2] 2 (4.8%) |
|  | Superinfection bacterial |  | [1] 1 (1.9%) |  |
| Injury, poisoning and procedural complications | #Total | [1] 1 (1.1%) | [1] 1 (1.9%) |  |
|  | Hepatobiliary procedural complication | [1] 1 (1.1%) |  |  |
|  | Procedural pneumothorax |  | [1] 1 (1.9%) |  |
| Investigations | #Total | [4] 4 (4.6%) | [8] 5 (9.6%) | [7] 4 (9.5%) |
|  | Alanine aminotransferase increased |  | [4] 3 (5.8%) |  |
|  | Amylase increased |  |  | [1] 1 (2.4%) |
|  | Aspartate aminotransferase increased | [1] 1 (1.1%) | [2] 2 (3.8%) | [2] 2 (4.8%) |
|  | Blood creatine phosphokinase increased | [1] 1 (1.1%) |  |  |
|  | Electrocardiogram QT prolonged | [1] 1 (1.1%) |  | [1] 1 (2.4%) |
|  | Fibrin D dimer increased |  |  | [1] 1 (2.4%) |
|  | Gamma-glutamyltransferase increased |  |  | [1] 1 (2.4%) |
|  | Hepatic enzyme increased |  | [2] 2 (3.8%) |  |
|  | Myocardial necrosis marker increased | [1] 1 (1.1%) |  |  |
|  | Neutrophil count decreased |  |  | [1] 1 (2.4%) |
| Metabolism and nutrition disorders | #Total |  | [1] 1 (1.9%) |  |
|  | Hypercalcaemia |  | [1] 1 (1.9%) |  |
| Musculoskeletal and connective tissue disorders | #Total | [4] 2 (2.3%) |  |  |
|  | Arthralgia | [1] 1 (1.1%) |  |  |
|  | Arthritis reactive | [1] 1 (1.1%) |  |  |
|  | Joint swelling | [1] 1 (1.1%) |  |  |
|  | Tendonitis | [1] 1 (1.1%) |  |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | #Total |  |  | [1] 1 (2.4%) |
|  | Neoplasm malignant |  |  | [1] 1 (2.4%) |
| Nervous system disorders | #Total | [1] 1 (1.1%) | [2] 2 (3.8%) | [2] 2 (4.8%) |
|  | Haemorrhage intracranial |  | [1] 1 (1.9%) |  |
|  | Headache |  |  | [1] 1 (2.4%) |
|  | Loss of consciousness |  |  | [1] 1 (2.4%) |
|  | Syncope | [1] 1 (1.1%) | [1] 1 (1.9%) |  |
| Renal and urinary disorders | #Total | [1] 1 (1.1%) |  | [1] 1 (2.4%) |
|  | Renal failure | [1] 1 (1.1%) |  | [1] 1 (2.4%) |
| Respiratory, thoracic and mediastinal disorders | #Total | [8] 7 (8%) | [5] 5 (9.6%) | [14] 9 (21.4%) |
|  | Bronchopleural fistula |  |  | [1] 1 (2.4%) |
|  | Chronic obstructive pulmonary disease |  |  | [2] 1 (2.4%) |
|  | Cough |  |  | [1] 1 (2.4%) |
|  | Dyspnoea | [1] 1 (1.1%) |  | [3] 1 (2.4%) |
|  | Pulmonary embolism | [1] 1 (1.1%) |  |  |
|  | Respiratory distress | [4] 4 (4.6%) | [1] 1 (1.9%) | [3] 2 (4.8%) |
|  | Respiratory failure | [2] 2 (2.3%) | [4] 4 (7.7%) | [4] 3 (7.1%) |
| Skin and subcutaneous tissue disorders | #Total |  | [1] 1 (1.9%) | [1] 1 (2.4%) |
|  | Alopecia |  | [1] 1 (1.9%) | [1] 1 (2.4%) |
| Vascular disorders | #Total | [2] 2 (2.3%) |  | [1] 1 (2.4%) |
|  | Hypotension |  |  | [1] 1 (2.4%) |
|  | Thrombophlebitis | [1] 1 (1.1%) |  |  |
|  | Thrombosis | [1] 1 (1.1%) |  |  |

## Serious Adverse Events

Serious Adverse Events by System Organ Class and Preferred term

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| System Organ Class | Preferred Term | SOC (N=87) | SOC + HCQ (N=52) | SOC + Remdesivir (N=42) |
| Gastrointestinal disorders | #Total | [1] 1 (1.1%) | [1] 1 (1.9%) |  |
|  | Abdominal pain | [1] 1 (1.1%) |  |  |
|  | Diarrhoea haemorrhagic |  | [1] 1 (1.9%) |  |
| General disorders and administration site conditions | #Total | [2] 2 (2.3%) |  | [1] 1 (2.4%) |
|  | Chest pain |  |  | [1] 1 (2.4%) |
|  | General physical health deterioration | [1] 1 (1.1%) |  |  |
|  | Pyrexia | [1] 1 (1.1%) |  |  |
| Hepatobiliary disorders | #Total | [1] 1 (1.1%) |  |  |
|  | Cholecystitis | [1] 1 (1.1%) |  |  |
| Infections and infestations | #Total | [1] 1 (1.1%) | [1] 1 (1.9%) | [1] 1 (2.4%) |
|  | COVID-19 | [1] 1 (1.1%) |  |  |
|  | Pneumonia bacterial |  |  | [1] 1 (2.4%) |
|  | Superinfection bacterial |  | [1] 1 (1.9%) |  |
| Injury, poisoning and procedural complications | #Total | [1] 1 (1.1%) | [1] 1 (1.9%) |  |
|  | Hepatobiliary procedural complication | [1] 1 (1.1%) |  |  |
|  | Procedural pneumothorax |  | [1] 1 (1.9%) |  |
| Investigations | #Total | [1] 1 (1.1%) | [3] 3 (5.8%) | [1] 1 (2.4%) |
|  | Alanine aminotransferase increased |  | [1] 1 (1.9%) |  |
|  | Aspartate aminotransferase increased |  |  | [1] 1 (2.4%) |
|  | Blood creatine phosphokinase increased | [1] 1 (1.1%) |  |  |
|  | Hepatic enzyme increased |  | [2] 2 (3.8%) |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | #Total |  |  | [1] 1 (2.4%) |
|  | Neoplasm malignant |  |  | [1] 1 (2.4%) |
| Nervous system disorders | #Total |  | [1] 1 (1.9%) | [1] 1 (2.4%) |
|  | Haemorrhage intracranial |  | [1] 1 (1.9%) |  |
|  | Loss of consciousness |  |  | [1] 1 (2.4%) |
| Renal and urinary disorders | #Total | [1] 1 (1.1%) |  | [1] 1 (2.4%) |
|  | Renal failure | [1] 1 (1.1%) |  | [1] 1 (2.4%) |
| Respiratory, thoracic and mediastinal disorders | #Total | [7] 6 (6.9%) | [4] 4 (7.7%) | [13] 8 (19%) |
|  | Bronchopleural fistula |  |  | [1] 1 (2.4%) |
|  | Chronic obstructive pulmonary disease |  |  | [2] 1 (2.4%) |
|  | Dyspnoea | [1] 1 (1.1%) |  | [3] 1 (2.4%) |
|  | Pulmonary embolism | [1] 1 (1.1%) |  |  |
|  | Respiratory distress | [3] 3 (3.4%) | [1] 1 (1.9%) | [3] 2 (4.8%) |
|  | Respiratory failure | [2] 2 (2.3%) | [3] 3 (5.8%) | [4] 3 (7.1%) |

## Suspected Unexpected Serious Adverse Reaction

Suspected Unexpected Serious Adverse Reaction by System Organ Class and Preferred term

|  |  |  |
| --- | --- | --- |
| System Organ Class | Preferred Term | Hydroxychloroquine + SOC |
| Gastrointestinal disorders | #Total | [1] 1 (1.9%) |
|  | Diarrhoea haemorrhagic | [1] 1 (1.9%) |

END